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Severe intellectual disability (ID) occurs in 0.5% of newborns and is
thought to be largely genetic in origin1,2. The extensive genetic het-
erogeneity of this disorder requires a genome-wide detection of all
types of genetic variation. Microarray studies and, more recently,
exome sequencing have demonstrated the importance of de novo
copy number variations (CNVs) and single-nucleotide variations
(SNVs) in ID, but the majority of cases remain undiagnosed3–6.
Hereweappliedwhole-genomesequencing to50patientswith severe
ID and their unaffected parents. All patients included had not re-
ceived a molecular diagnosis after extensive genetic prescreening,
including microarray-based CNV studies and exome sequencing.
Notwithstanding this prescreening, 84 de novo SNVs affecting the
coding regionwere identified,which showeda statistically significant
enrichment of loss-of-function mutations as well as an enrichment
for genes previously implicated in ID-related disorders. In addi-
tion, we identified eight de novo CNVs, including single-exon and
intra-exonic deletions, as well as interchromosomal duplications.
TheseCNVsaffectedknownIDgenesmore frequently thanexpected.
On the basis of diagnostic interpretation of all de novo variants, a
conclusive genetic diagnosis was reached in 20 patients. Together
with one compound heterozygous CNV causing disease in a recess-
ivemode, this results in a diagnostic yield of 42% in this extensively
studied cohort, and 62% as a cumulative estimate in an unselected
cohort. These results suggest that de novo SNVs andCNVs affecting
the coding region are a major cause of severe ID. Genome sequen-
cing can be applied as a single genetic test to reliably identify and
characterize the comprehensive spectrum of genetic variation, pro-
viding a genetic diagnosis in themajority of patients with severe ID.
Whole-genomesequencing (WGS) is considered to be themost com-
prehensive genetic test so far7, but widespread application to patient
diagnostics has been hampered by challenges in data analysis, the un-
known diagnostic potential of the test, and relatively high costs. In this
study, the genomes of 50 patients with severe ID and their unaffected
parents were sequenced to an average genome-wide coverage of 80 fold
(SupplementaryTable 1)8. Before inclusion in the study, patients under-
went an extensive clinical and genetic work-up, including targeted gene
analysis, genomic microarray analysis and whole-exome sequencing
(WES)6, but no molecular diagnosis could be established (Fig. 1).
On average, 98% of the genome was called for both alleles, giving
rise to 4.4 million SNVs and 276 CNVs per genome (Supplementary
Table 2). WGS identified an average of 22,186 coding SNVs per indi-
vidual, encompassing more than 97% of variants identified previously
byWES (Supplementary Tables 2, 3). We focused our analysis first on
de novo SNVs and CNVs because of their importance in ID4. On aver-
age, 82high-confidencepotentialdenovo SNVswere called per genome
(Supplementary Methods and Supplementary Table 4), which is in
concordance with previous studies9–11. Systematic validation by Sanger
sequencing of putative de novo variants in the protein-coding regions
resulted in a total of 84 coding de novomutations in 50 patients, giving
rise to aprotein-codingdenovo substitution rateof 1.58 (Supplementary
Methods and Supplementary Tables 5, 6, 7, 8). This rate exceeds all
previously published substitution rates11–15 obtained usingWES (Sup-
plementary Table 9), as well as inferred substitution rates (P5 3.583
1025) (ref. 14). In addition, this set of de novomutations is significantly
enriched for loss-of-functionmutations (P5 1.5943 1025; Supplemen-
tary Methods).
Next, we investigated whether de novomutations occurred in genes
that have previously been identified in other patients with ID and/or
overlapping phenotypes such as autism, schizophrenia or epilepsy12–19.
To this end, we compiled two sets of genes, one set containing 528
genes harbouring mutations in at least five patients with ID (referred
to as ‘known ID genes’) and one list containing 628 genes harbouring
mutations in at least one, but less than five patients (referred to as ‘can-
didate IDgenes’) (SupplementaryMethods). It has recently been shown
thatMendelian disease genes are less tolerant to functional genetic var-
iation than genes that do not cause any known disease20. In line with
this, both the set of known ID genes and the set of candidate ID genes
indeed showed significantly less tolerance for functional variation (P,
1.03 1026 for both sets; Extended Data Fig. 1 and Supplementary
Methods). Subsequent analysis of our 84 de novomutations at the gene
level revealed significantlymoremutations in known IDgenes than ex-
pected (nine genes, P5 0.04; Supplementary Table 10). Mutations in
these knownIDgenes included four insertion/deletion events, twonon-
sensemutations and threehighly conservedmissensemutations, thereby
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Figure 1 | Study design and diagnostic yield in patients with severe ID per
technology. Diagnostic yield for patientswith severe ID (IQ, 50), specified by
technology: genomic microarrays, WES and WGS. Percentages indicate the
number of patients in whom a conclusive cause was identified using the
specified technique. Brackets indicate the group of patients in whomno genetic
cause was identified andwhose DNAwas subsequently analysed using the next
technology. WES data are updated with permission from ref. 6 (see
Supplementary Methods).
0 0 M O N T H 2 0 1 4 | V O L 0 0 0 | N A T U R E | 1
Macmillan Publishers Limited. All rights reserved©2014
27 
 
Supplementary tables 
Supplementary Table 1: Detailed cohort description of 50 trios studied by WGS 
 
Level of ID Number of patients 
 
Epilepsy   
IQ <30 31 
 
Yes 23 
IQ 30-50 19 
 
No 27 
IQ 50-70 0 
   
   
Abnormalities on brain imaging 
Gender   
 
Yes 17 
Male 26 
 
No 19 
Female 24 
 
Not assessed 14 
     Age Groups   
 
Cardiac malformations 
<10 yrs 26 
 
Yes 1 
10-20 yrs 8 
 
No 49 
>20 yrs 16 
   
   
Abnormalities of the urogenital system 
Sibship size   
 
Yes 11 
1 4 
 
No 39 
2 27 
   3 17 
   ≥4 2 
   
     Multiple Congenital Anomalies 
   0 27 
   1 17 
   2 6 
   
     Short Stature   
   Yes 15 
   No 35 
   
     Microcephaly   
   Yes 18 
   No 32 
   
     Macrocephaly   
   Yes 3 
   No 47 
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Extended Data Table 2 | De novo SNVs of potential clinical relevance identified using WGS
A dash indicates genes that have not yet been implicated in ID, but fulfil the criteria for diagnostic reporting of a pathogenic variant (that is, a possible cause for ID).
{Predicted effect on splicing.
{PhyloP score for nonsense and frameshift mutations is not provided as this are deleterious mutations regardless of their evolutionary conservation.
1 ‘Known’ refers to known ID gene whereas ‘Candidate’ refers to a gene that is listed on the candidate ID gene list.
ISince the inclusion of this patient in this study, the same de novomutation in ALG13 has been described elsewhere16. Thismay suggest that this mutation, despite its low conservation and the identification of a
nonsense mutation in RAI1, may also contribute to the disease phenotype in this patient. See also Supplementary Table 8 legend.
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prehensive genetic test so far7, but widespread application to patient
diagnostics has been hampered by challenges in data analysis, the un-
known diagnostic potential of the test, and relatively high costs. In this
study, the genomes of 50 patients with severe ID and their unaffected
parents were sequenced to an average genome-wide coverage of 80 fold
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went an extensive clinical and genetic work-up, including targeted gene
analysis, genomic microarray analysis and whole-exome sequencing
(WES)6, but no molecular diagnosis could be established (Fig. 1).
On average, 98% of the genome was called for both alleles, giving
rise to 4.4 million SNVs and 276 CNVs per genome (Supplementary
Table 2). WGS identified an average of 22,186 coding SNVs per indi-
vidual, encompassing more than 97% of variants identified previously
byWES (Supplementary Tables 2, 3). We focused our analysis first on
de novo SNVs and CNVs because of their importance in ID4. On aver-
age, 82high-confidencepotentialdenovo SNVswere called per genome
(Supplementary Methods and Supplementary Table 4), which is in
concordance with previous studies9–11. Systematic validation by Sanger
sequencing of putative de novo variants in the protein-coding regions
resulted in a total of 84 coding de novomutations in 50 patients, giving
rise to aprotein-codingdenovo substitution rateof 1.58 (Supplementary
Methods and Supplementary Tables 5, 6, 7, 8). This rate exceeds all
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plementary Table 9), as well as inferred substitution rates (P5 3.583
1025) (ref. 14). In addition, this set of de novomutations is significantly
enriched for loss-of-functionmutations (P5 1.5943 1025; Supplemen-
tary Methods).
Next, we investigated whether de novomutations occurred in genes
that have previously been identified in other patients with ID and/or
overlapping phenotypes such as autism, schizophrenia or epilepsy12–19.
To this end, we compiled two sets of genes, one set containing 528
genes harbouring mutations in at least five patients with ID (referred
to as ‘known ID genes’) and one list containing 628 genes harbouring
mutations in at least one, but less than five patients (referred to as ‘can-
didate IDgenes’) (SupplementaryMethods). It has recently been shown
thatMendelian disease genes are less tolerant to functional genetic var-
iation than genes that do not cause any known disease20. In line with
this, both the set of known ID genes and the set of candidate ID genes
indeed showed significantly less tolerance for functional variation (P,
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Figure 1 | Study design and diagnostic yield in patients with severe ID per
technology. Diagnostic yield for patientswith severe ID (IQ, 50), specified by
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also showing an enrichment for loss-of-function mutations (P5 4.88
3 1026). Also, a significant enrichment fordenovomutations (n5 10)
in candidate ID genes was identified (P5 0.013), including three loss-
of-functionmutations (P5 0.02) and three highly conservedmissense
mutations (Supplementary Table 11). These mutated known and can-
didate ID genes showed a diminished tolerance to functional variation
(P5 5.593 1026 and P5 0.0042, respectively), similar to what was
observed for the entire set of known and candidate ID genes. These sta-
tistical analyses on SNVs together indicate that we not only identified
significantly more de novo mutations in these 50 patients with severe
ID, but also that they are more severe and occur more often in known
or candidate ID genes.
In addition to the detection of de novo SNVs and small insertion/
deletionevents, a total of eightdenovo structural variants, orCNVs,were
identified andvalidated.These structural variants included fivedeletions,
a tandemduplication, an interchromosomal duplication and one com-
plex inversion/duplication/deletion event (ExtendedData Table 1). All
of these events hadpreviously remainedundetectedbydiagnosticmicro-
array analysis. Threedeletionswere smaller than10kilobases (kb) in size,
including two single-exon deletions and one intra-exonic deletion. Four
of the de novo deletions encompassed a known ID gene and one a can-
didate IDgene, resulting in a significant enrichment forCNVs affecting
known ID genes (P5 0.015). In addition, six de novoCNVs contained
agene inwhichexonicCNVsoccur significantlymore frequent inpatients
with ID (n5 7,743) compared to control individuals (n5 4,056) (Ex-
tended Data Table 1). Local realignment of sequence reads provided
accurate single-nucleotide breakpoint information for six of the events,
whichwas readily confirmedby breakpoint-spanningpolymerase chain
reactions (PCRs) (Extended Data Figs 2–5). Discordant reads not only
provided the precise breakpoint sequences, but also positional informa-
tion forduplicated sequences. Inone case apartial duplicationofTENM3
on chromosome 4 was invertedly inserted into IQSEC2 on the X chro-
mosome. RNA studies confirmed the formation of a stable in-frame
IQSEC2-TENM3 gene fusion (Fig. 2), thereby suggesting that disruption
of IQSEC2, a known ID gene, may well contribute to the patient’s phe-
notype. The contribution of such fusion genes to disease is well known
in tumorigenesis, but has only recently been systematically investigated
in neurodevelopmental disorders21.
Interestingly, three of ten de novo SNVs occurring in candidate ID
genes seemed to be present in a mosaic state in the proband on the
basis of the fraction of sequence reads containing the mutated allele.
Sanger sequencing and amplicon-based deep sequencing confirmed
the presence of mosaic mutations in these patients, at levels of 21%
(PIAS1), 22% (HIVEP2) and 20% (KANSL2) (ExtendedData Fig. 6), of
whichKANSL2 is predicted to be deleterious owing to altered splicing.
It is important that mosaic events like these can be detected byWGS as
they are a known cause of genetic disease22. An additional advantage of
genome sequencing over other approaches is that it may reveal patho-
genic mutations in the non-coding part of the genome. In a systematic
attempt to study the role of de novo non-coding mutations in ID, we
selected all high-confidence candidatedenovomutations located either
within the promoter regions, introns or untranslated regions of all
known ID genes and validated 43 mutations (Supplementary Tables
12, 13).Annotationof thesemutationsusing severalENCODEresources23,
including chromatin state segments of nine human cell types and
transcription-factor-binding sites, did not reveal potential pathogenic
non-codingmutations (SupplementaryMethods).However, ourunder-
standing of non-coding variation is still limited and extensive func-
tional follow-up will be required to determine its role in disease23.
In addition to the statistical analysis of our data, we also assessed the
impact of our genome sequencing study in a clinical diagnostic setting,
inwhichvariant interpretation is combinedwithanevaluationofpatients’
phenotypes tomake a diagnostic decision on a per patient basis. There-
fore, all de novo coding mutations (SNVs and CNVs) were evaluated
for pathogenicity on the basis of established diagnostic criteria (Sup-
plementaryMethods andExtendedDataTable 1)24–27. For patientswith
de novo mutations in a known or candidate ID gene this clinical dia-
gnostic assessment also includeda comparisonof thephenotypeobserved
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Figure 2 | Detected duplication of a chromosome 4 region into the
X-chromosomal IQSEC2 gene. a–d, Graphical representation of a de novo
duplication–insertion event in patient 31. a, Circos plot with chromosome
numbers and de novomutations in the outer shell. Red bars represent genome-
wide potential de novo SNVs, whereas blue lines represent potential de novo
CNVs/structural variants. Inner shell represents the location of known ID
genes (red marks) with the respective gene names. Green line illustrates a
duplication event on chromosome 4, which is inserted into chromosome X.
b, Details for inserted duplication event on chromosomeX.The last six exons of
TENM3 are inserted in inverted orientation into intron 2 of IQSEC2, predicted
to result in an in-frame IQSEC2-TENM3 fusion gene. ex., exon. c, d, PCR (c) on
and Sanger sequencing (d) of complementary DNA junction fragment in
patient 31. Lanes in c represent the following: M, 100 bp marker; 1, cDNA of
patient with cyclohexamide treatment; 2, cDNA of patient without
cyclohexamide treatment; 3, control cDNA with cyclohexamide treatment; 4,
control cDNA without cyclohexamide treatment. Our data verify the presence
of a fusion gene in patient 31 that is suggested to escape nonsense-mediated
decay.
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inour patientwith those reported in the literature.Conclusivediagnoses
were reached for fourteen patients with de novo mutations affecting
a known ID gene (nine SNVs and five CNVs), as well as for six patients
with de novomutations affecting a candidate ID gene (four SNVs and
twoCNVs) (ExtendedDataTables 1, 2 andSupplementaryTables 8, 14).
Although family history for IDwas negative for all patients included
in this study, we evaluated the presence of recessively inherited causes
ofdiseasedue tomutations inknownIDgenes (SupplementaryTable 10).
Wedidnot findX-linkedmaternally inherited variants inmale patients
consistent with the patient’s phenotype, nor did we identify relevant
homozygous or compound heterozygous SNVs on the autosomes.We
did, however, identify a single proband carrying compound heterozyg-
ous deletions affecting the VPS13B gene, one of the known ID genes.
Subsequent breakpoint sequencing confirmed that the 122 kb deletion,
affecting exons 12–18,was paternally inheritedwhereas the 1.7 kbdele-
tion of the last exon was maternally inherited (Extended Data Fig. 7).
Notably, Cohen syndrome28 was part of the differential diagnosis of
this patient but no causative SNVs or CNVs were previously detected
in this gene by direct Sanger sequencing or microarray analysis.
Taken together, a conclusive diagnosis wasmade in 21 of 50 patients
with severe ID in thiswell-studied cohort (42%;Table1 and Supplemen-
tary Table 15). The experimental set-up of our study allowed us to es-
timate the diagnostic yield of WGS in an unbiased cohort of such
patients (Fig. 1).On thebasis of establisheddiagnostic rates for genomic
microarrays (12%) and WES (27%) in patients from the same large
cohort6,26, the cumulative estimate for WGS to reach a conclusive gen-
etic diagnosis is 62%, of which 60% by de novo events (39% SNVs, 21%
CNVs) and 2% by recessive inheritance (Fig. 3 and Supplementary
Methods). The role of de novo somatic mutations and de novomuta-
tions outside the coding regions remains to be fully explored.
METHODS SUMMARY
Patients were selected to have severe ID (IQ , 50) and negative results on diag-
nostic genomicmicroarrays and exome sequencing6 (Fig. 1).WGS was performed
by Complete Genomics as previously described8,29. De novo SNVs were identified
using Complete Genomics’ cgatools ‘calldiff’ program. CNVs and structural var-
iants were reported by Complete Genomics on the basis of read-depth deviations
anddiscordant read pairs, respectively.DenovoCNVs and structural variantswere
then identified by excluding variants with minimal evidence or overlapping with
CNVsandstructural variants identified in theparentsor control data sets.All variants
were annotated using an in-house analysis pipeline and subsequently prioritized for
validation based on their confidence level (low/medium/high) and location in the
genome (coding/non-coding). High-confidence candidate de novo mutations in
non-coding variants in known ID genes were prioritized on the basis of evolution-
ary conservation and overlap with ENCODE chromatin state segments and tran-
scription-factor-binding sites23. Statistical overrepresentationofmutations inknown
and candidate IDgene listswas calculatedusing Fisher’s exact test based onRefSeq
genes. Enrichments for loss-of-functionCNVeventswere calculatedusing the exact
Poisson test. To clinically interpret (de novo) mutations, each variant (both CNV
and SNV) was assessed for mutation impact as well as functional relevance to ID
according to diagnostic protocols for variant interpretation6,24–27. The diagnostic
yield ofWGS in an unbiased cohort was calculated based on cumulative estimates
of diagnostic yield per technology (genomic microarray, WES and WGS).
Online Content Any additional Methods, ExtendedData display items and Source
Data are available in the online version of the paper; references unique to these
sections appear only in the online paper.
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Table 1 | Diagnostic yield by WGS for a pre-screened cohort of 50 ID
trios
Genetic cause Number of patients
Total positive diagnosis 21
Dominant de novo
Autosomal SNV
Autosomal CNV
X-linked SNV
X-linked CNV
Recessive
Homozygous
Compound heterozygous
X-linked
20
11
5
2
2
1
0
1
0
Candidate ID genes 8
No diagnosis 21
Conclusive dominant de novo cause (60%)
Conclusive inherited cause (2%)
No cause (38%)
CNV
SNV
CNV
Figure 3 | Pie chart showing role of de novo mutations in severe ID. Con-
tribution of genetic causes to severe ID on the basis of the cumulative estimates
provided per technology. Our data indicate that de novomutations are a major
cause of severe ID. Note, small variants include SNVs and insertion/deletion
events whereas large variants include structural variants andCNVs (.500 bp).
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inour patientwith those reported in the literature.Conclusivediagnoses
were reached for fourteen patients with de novo mutations affecting
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with de novomutations affecting a candidate ID gene (four SNVs and
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ous deletions affecting the VPS13B gene, one of the known ID genes.
Subsequent breakpoint sequencing confirmed that the 122 kb deletion,
affecting exons 12–18,was paternally inheritedwhereas the 1.7 kbdele-
tion of the last exon was maternally inherited (Extended Data Fig. 7).
Notably, Cohen syndrome28 was part of the differential diagnosis of
this patient but no causative SNVs or CNVs were previously detected
in this gene by direct Sanger sequencing or microarray analysis.
Taken together, a conclusive diagnosis wasmade in 21 of 50 patients
with severe ID in thiswell-studied cohort (42%;Table1 and Supplemen-
tary Table 15). The experimental set-up of our study allowed us to es-
timate the diagnostic yield of WGS in an unbiased cohort of such
patients (Fig. 1).On thebasis of establisheddiagnostic rates for genomic
microarrays (12%) and WES (27%) in patients from the same large
cohort6,26, the cumulative estimate for WGS to reach a conclusive gen-
etic diagnosis is 62%, of which 60% by de novo events (39% SNVs, 21%
CNVs) and 2% by recessive inheritance (Fig. 3 and Supplementary
Methods). The role of de novo somatic mutations and de novomuta-
tions outside the coding regions remains to be fully explored.
METHODS SUMMARY
Patients were selected to have severe ID (IQ , 50) and negative results on diag-
nostic genomicmicroarrays and exome sequencing6 (Fig. 1).WGS was performed
by Complete Genomics as previously described8,29. De novo SNVs were identified
using Complete Genomics’ cgatools ‘calldiff’ program. CNVs and structural var-
iants were reported by Complete Genomics on the basis of read-depth deviations
anddiscordant read pairs, respectively.DenovoCNVs and structural variantswere
then identified by excluding variants with minimal evidence or overlapping with
CNVsandstructural variants identified in theparentsor control data sets.All variants
were annotated using an in-house analysis pipeline and subsequently prioritized for
validation based on their confidence level (low/medium/high) and location in the
genome (coding/non-coding). High-confidence candidate de novo mutations in
non-coding variants in known ID genes were prioritized on the basis of evolution-
ary conservation and overlap with ENCODE chromatin state segments and tran-
scription-factor-binding sites23. Statistical overrepresentationofmutations inknown
and candidate IDgene listswas calculatedusing Fisher’s exact test based onRefSeq
genes. Enrichments for loss-of-functionCNVeventswere calculatedusing the exact
Poisson test. To clinically interpret (de novo) mutations, each variant (both CNV
and SNV) was assessed for mutation impact as well as functional relevance to ID
according to diagnostic protocols for variant interpretation6,24–27. The diagnostic
yield ofWGS in an unbiased cohort was calculated based on cumulative estimates
of diagnostic yield per technology (genomic microarray, WES and WGS).
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Table 1 | Diagnostic yield by WGS for a pre-screened cohort of 50 ID
trios
Genetic cause Number of patients
Total positive diagnosis 21
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X-linked SNV
X-linked CNV
Recessive
Homozygous
Compound heterozygous
X-linked
20
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1
0
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Candidate ID genes 8
No diagnosis 21
Conclusive dominant de novo cause (60%)
Conclusive inherited cause (2%)
No cause (38%)
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Figure 3 | Pie chart showing role of de novo mutations in severe ID. Con-
tribution of genetic causes to severe ID on the basis of the cumulative estimates
provided per technology. Our data indicate that de novomutations are a major
cause of severe ID. Note, small variants include SNVs and insertion/deletion
events whereas large variants include structural variants andCNVs (.500 bp).
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inour patientwith those reported in the literature.Conclusivediagnoses
were reached for fourteen patients with de novo mutations affecting
a known ID gene (nine SNVs and five CNVs), as well as for six patients
with de novomutations affecting a candidate ID gene (four SNVs and
twoCNVs) (ExtendedDataTables 1, 2 andSupplementaryTables 8, 14).
Although family history for IDwas negative for all patients included
in this study, we evaluated the presence of recessively inherited causes
ofdiseasedue tomutations inknownIDgenes (SupplementaryTable 10).
Wedidnot findX-linkedmaternally inherited variants inmale patients
consistent with the patient’s phenotype, nor did we identify relevant
homozygous or compound heterozygous SNVs on the autosomes.We
did, however, identify a single proband carrying compound heterozyg-
ous deletions affecting the VPS13B gene, one of the known ID genes.
Subsequent breakpoint sequencing confirmed that the 122 kb deletion,
affecting exons 12–18,was paternally inheritedwhereas the 1.7 kbdele-
tion of the last exon was maternally inherited (Extended Data Fig. 7).
Notably, Cohen syndrome28 was part of the differential diagnosis of
this patient but no causative SNVs or CNVs were previously detected
in this gene by direct Sanger sequencing or microarray analysis.
Taken together, a conclusive diagnosis wasmade in 21 of 50 patients
with severe ID in thiswell-studied cohort (42%;Table1 and Supplemen-
tary Table 15). The experimental set-up of our study allowed us to es-
timate the diagnostic yield of WGS in an unbiased cohort of such
patients (Fig. 1).On thebasis of establisheddiagnostic rates for genomic
microarrays (12%) and WES (27%) in patients from the same large
cohort6,26, the cumulative estimate for WGS to reach a conclusive gen-
etic diagnosis is 62%, of which 60% by de novo events (39% SNVs, 21%
CNVs) and 2% by recessive inheritance (Fig. 3 and Supplementary
Methods). The role of de novo somatic mutations and de novomuta-
tions outside the coding regions remains to be fully explored.
METHODS SUMMARY
Patients were selected to have severe ID (IQ , 50) and negative results on diag-
nostic genomicmicroarrays and exome sequencing6 (Fig. 1).WGS was performed
by Complete Genomics as previously described8,29. De novo SNVs were identified
using Complete Genomics’ cgatools ‘calldiff’ program. CNVs and structural var-
iants were reported by Complete Genomics on the basis of read-depth deviations
anddiscordant read pairs, respectively.DenovoCNVs and structural variantswere
then identified by excluding variants with minimal evidence or overlapping with
CNVsandstructural variants identified in theparentsor control data sets.All variants
were annotated using an in-house analysis pipeline and subsequently prioritized for
validation based on their confidence level (low/medium/high) and location in the
genome (coding/non-coding). High-confidence candidate de novo mutations in
non-coding variants in known ID genes were prioritized on the basis of evolution-
ary conservation and overlap with ENCODE chromatin state segments and tran-
scription-factor-binding sites23. Statistical overrepresentationofmutations inknown
and candidate IDgene listswas calculatedusing Fisher’s exact test based onRefSeq
genes. Enrichments for loss-of-functionCNVeventswere calculatedusing the exact
Poisson test. To clinically interpret (de novo) mutations, each variant (both CNV
and SNV) was assessed for mutation impact as well as functional relevance to ID
according to diagnostic protocols for variant interpretation6,24–27. The diagnostic
yield ofWGS in an unbiased cohort was calculated based on cumulative estimates
of diagnostic yield per technology (genomic microarray, WES and WGS).
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events whereas large variants include structural variants andCNVs (.500 bp).
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METHODS
Patient selection. Patients were selected to have severe ID (IQ, 50) and negative
results ondiagnostic genomicmicroarrays and exome sequencing6 (Fig. 1 andSup-
plementary Methods).
Whole genome sequencing.WGSwas performed by Complete Genomics as pre-
viously described8. Sequence readsweremapped to the referencegenome (GRCh37)
and variants were called by local de novo assembly according to the methods pre-
viously described29.
Identification of de novo small variants. De novo SNVs were identified using
Complete Genomics’ cgatools ‘calldiff’ program. On the basis of the rank order of
the two confidence scores of a de novo mutation, we binned the variants in three
groups: low confidence (at least one score, 0), medium confidence (both scores
$ 0 but at least one , 5) and high confidence (both scores$ 5) (Supplementary
Methods).
IdentificationofX-linked, recessive and compoundheterozygousSNVs.Mater-
nally inheritedX-linked variants (inmalepatients), homozygous variants and com-
pound heterozygous variant pairs were identified using the Complete Genomics’
cgatools ‘listvariants’ and ‘testvariants’ programs to select variants according to
their respective segregation. Compound heterozygous variants affecting the same
gene were identified using RefSeq gene annotation (Supplementary Methods).
Identification of de novoCNVs and structural variants.CNVswere reported by
Complete Genomics on the basis of read-depth deviations across 2 kb windows.
Structural variantswere reported byCompleteGenomics based ondiscordant read
pairs.DenovoCNVs/structural variants were then identified by excluding variants
withminimal evidence or overlapping with CNVs/structural variants identified in
the parents or control data sets (Supplementary Methods).
Generation of lists for known and candidate ID genes. To prioritize and for
subsequent interpretation of de novo variants for each patient individually, two
gene lists were generated, one containing known ID genes (defined by five ormore
patients with ID having a mutation in the respective gene) and one containing
candidate ID genes (defined by at least one but less than five patients with ID (or a
related phenotype) showing a mutation in the respective gene) (Supplementary
Methods).
Prioritization of clinically relevant SNVs and CNVs or structural variants.All
SNVswere annotated using an in-house analysis pipeline.Variantswereprioritized
for validation in two distinct ways: (1) medium and high-confidence de novo
SNVs anddenovoCNVs/structural variants affecting coding regions and/or canon-
ical splice sites; and (2) all potential de novo variants within known ID genes, irre-
spective of confidence level. Interpretationof codingdenovovariantswasperformed
as described previously6. High-confidence candidate de novo mutations in non-
coding variantswere prioritized on the basis of evolutionary conservation and over-
lapwith ENCODEchromatin state segments and transcription-factor-binding sites
(Supplementary Methods)23.
Clinical interpretation ofmutations.To clinically interpret (de novo)mutations,
each de novo mutation (both CNV and SNV) was assessed for mutation impact
as well as functional relevance to ID according to diagnostic protocols for variant
interpretation24–27 that are used in our accredited diagnostic laboratory for genetic
analysis (accredited to the ‘CCKL Code of Practice’, which is based on EN/ISO
15189 (2003), registration numbers R114/R115, accreditation numbers 095/103)
(Supplementary Methods).
Statistical analysis. Overrepresentation of mutations in gene lists was calculated
usingFisher’s exact test basedon the total coding size of allRefSeq genes and coding
size of the genes from the respective gene list.Overrepresentationof loss-of-function
mutationswas calculatedusingFisher’s exact test basedonpublished control cohorts.
Enrichments for loss-of-functionCNVeventswere calculated using the exact Pois-
son test. Enrichment for known ID genes was calculated using Fisher’s exact test
and odds ratios were calculated to compare the frequency of exonic CNVs in ID
and control cohorts, respectively (Supplementary Methods).
Calculation of diagnostic yield.Our in-house phenotypic database contains 1,489
patients with severe ID who have all had a diagnostic genomic microarray in the
time period 2003–2013. In 173 (11.6%) of these patients, a de novoCNVwas iden-
tified as a cause of ID. Subsequently, 100 array-negative patients were subjected to
WES, which resulted in a de novo cause for ID in 27% of patients. Of all WES-
negative patients, 50 were selected for this WGS study, in which 42% obtained a
conclusive genetic cause.Cumulative estimateswere subsequently determinedusing
the diagnostic yield per technology (Supplementary Methods).
29. Carnevali, P. et al. Computational techniques for human genome resequencing
using mated gapped reads. J. Comput. Biol. 19, 279–292 (2012).
30. MacArthur, D. G. et al. A systematic survey of loss-of-function variants in human
protein-coding genes. Science 335, 823–828 (2012).
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Extended Data Figure 1 | Boxplots of rare missense burden in different
gene sets. Boxplots showing the difference in tolerance for rare missense
variation in the general population. The vertical axis shows the distribution for
each gene set of the number of rare (,1% in NHLBI Exome Sequencing
Project)missense variants divided by the number of rare synonymous variants.
From left to right the following gene sets are depicted: all 18,424 RefSeq genes,
170 loss-of-function tolerant genes from ref. 30, all 528 known ID genes
(Supplementary Table 10), all 628 candidate ID genes (Supplementary Table
11), 9 known ID genes in which de novomutations were identified in this study
(Supplementary Table 8), and 10 candidate ID genes in which de novo
mutations were identified in this study (Supplementary Table 8).
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Extended Data Figure 2 | Structural variant involving STAG1 (patient 40).
a–c, CNV identified using WGS in patient 40, including the STAG1 gene.
a, Chromosome 3 profile (log2 test over reference (T/R) ratios) based on
read-depth information for patient, father and mother. Black arrow points
towards the de novo event in patient 40. b, Genic contents of deletion. Grey
arrows show primers used to amplify the junction fragment. c, Details on the
proximal and distal breakpoints, showing the ‘fragmented’ sequence at both
ends. Breakpoints are provided in Extended Data Table 1.
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Extended Data Figure 2 | Structural variant involving STAG1 (patient 40).
a–c, CNV identified using WGS in patient 40, including the STAG1 gene.
a, Chromosome 3 profile (log2 test over reference (T/R) ratios) based on
read-depth information for patient, father and mother. Black arrow points
towards the de novo event in patient 40. b, Genic contents of deletion. Grey
arrows show primers used to amplify the junction fragment. c, Details on the
proximal and distal breakpoints, showing the ‘fragmented’ sequence at both
ends. Breakpoints are provided in Extended Data Table 1.
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Extended Data Figure 2 | Structural variant involving STAG1 (patient 40).
a–c, CNV identified using WGS in patient 40, including the STAG1 gene.
a, Chromosome 3 profile (log2 test over reference (T/R) ratios) based on
read-depth information for patient, father and mother. Black arrow points
towards the de novo event in patient 40. b, Genic contents of deletion. Grey
arrows show primers used to amplify the junction fragment. c, Details on the
proximal and distal breakpoints, showing the ‘fragmented’ sequence at both
ends. Breakpoints are provided in Extended Data Table 1.
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ExtendedData Figure 3 | Structural variant involving SHANK3 (patient 5).
a–c, CNV identified using WGS in patient 5, including the SHANK3 gene.
a, Detail of chromosome 22 profile (log2 T/R ratios) based on read-depth
information for patient, father and mother. Red dots in top panel show ratios
indicating the de novo deletion in patient 5. b, Genic content of the deletion.
c, Sanger validation for the junction fragment. Dotted vertical line indicates
the breakpoint with sequence on the left side originating from sequence
proximal to SHANK3 and on the right side sequence that originates from
sequence distal to ACR. Breakpoints are provided in Extended Data Table 1.
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Extended Data Figure 4 | Single-exon deletion involving SMC1A (patient
48). a, Schematic depiction of the deletion identified in patient 48 involving a
single exon of SMC1A. Pink horizontal bar highlights the exon that was deleted
in the patient. b, Details at the genomic level of the deletion including
exon 16, with Sanger sequence validation of the breakpoints. Junction is
indicated by a black vertical dotted line. Breakpoints are provided in Extended
Data Table 1.
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Extended Data Figure 5 | Intra-exonic deletion involving MECP2 (patient
18). a, Schematic depiction of the deletion identified in patient 18, which is
located within exon 4 ofMECP2. Initial Sanger sequencing in a diagnostic
setting could not validate the deletion as the primers used to amplify exon 4
removed the primer-binding sites (FW2 and RV1 respectively). Multiplex
ligation probe amplification (MLPA) analysis for CNV detection showed
normal results as the MLPA primer-binding sites were located just outside
of the deleted region. b, Combining primers FW1 and RV2 amplified the
junction fragment, clearly showing the deletion within exon 4. Of note, the
background underneath the Sanger sequence is derived from the wild-type
allele. Breakpoints are provided in Extended Data Table 1.
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Extended Data Figure 6 | Confirmation of mosaic mutations in PIAS1,
HIVEP2 and KANSL2. a–c, Approaches used to confirm the presence of
mosaicmutations in PIAS1 (a),HIVEP2 (b) andKANSL2 (c). Images and read-
depth information showing the base counts in the BAM files (left) indicated
that the variants/wild-type allele were not in a 50%/50% distribution. Sanger
sequencing (middle) then confirmed the variant to be present in the patient,
and absent in the parents (data from parents not shown), again indicating that
the mutation allele is underrepresented. Guided by these two observations,
amplicon-based deep sequencing using Ion Torrent subsequently confirmed
the mosaic state of the mutations (right). On the basis of deep sequencing,
percentages of mosaicism for PIAS1, HIVEP2 and KANSL2 were estimated at
21%, 22% and 20%, respectively.
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Extended Data Figure 7 | Compound heterozygous structural variation
affectingVPS13B (patient 12). a,b, CNVs ofVPS13B identified usingWGS in
patient 12. a, Schematic representation ofVPS13B, with vertical bars indicating
coding exons. In patient 12 two deletions were identified, one,122 kb in size
which was inherited from his father, and another ,2 kb in size, which was
inherited from his mother and consisted only of a single exon. b, Both CNV
junction fragments were subsequently validated using Sanger sequencing. Left,
junction fragment from the paternally inherited deletion. Right, junction
fragment from the maternally inherited deletion. Breakpoints are provided in
Extended Data Table 1.
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Extended Data Table 1 | Large variants of potential clinical relevance identified using WGS and probability of exonic CNVs occurring in
affected and control individuals for these loci
Geneshighlighted in bold are either listed as known IDgenes or candidate ID genes. Please note that all patients had250KSNPmicroarrays. Re-evaluation of these data showed that for all but oneCNV thenumber
of probes within the region was insufficient, either because of the small genomic size of the CNV, or due to uneven genome-wide probe spacing leaving fewer probes than required for the hidden Markov model
algorithms to be identified.
*Primary method used to identify the rearrangement (see also Supplementary Methods).
{Not assessed at base-pair level due to complexity of CNV event including an inversion, duplication and deletion.
{Not assessed at base-pair level as the CNV event, involving a known microdeletion syndrome region, is mediated by low-copy repeats.
1Single exon.
INumber of genes affected rather than individual gene names are provided due to the large number of genes.
"Observed 13 times in Decipher.
#Corrected for multiple testing using Benjamini–Hochberg with a false discovery rate (FDR) of 0.1.
VPS13B recessive ID gene.
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Table 1: Re-evaluated molecular diagnosis in 100 patients with severe ID after publication of diagnostic exome 
sequencing in patients with severe ID. 
Patient ID in 
de Ligt et al 
Molecular 
diagnosis  
Based on 
[gene] 
(inheritance) 
 
Re-evalutated 
molecular 
diagnosis 
Based on [gene] 
(inheritance) Change due to: 
4 Highly likely PDHA1  (X-linked)  NO - 
X-linked variant does not 
segregate 
             
5 Possibly PHIP  (de novo)  Highly likely 
PHIP  
(de novo) 
In house 2nd case identified 
through diagnostic WES in 
patient with severe ID 
             
6 Possibly PSMA7  (de novo)  Highly likely 
EHMT1 deletion 
 (de novo) 
CNV calling on WES data 
identified deletion of EHMT1 
(de novo) 
             
14 NO    Highly likely 
DDX3X 
 (de novo) 
Bioinformatic re-analysis of 
WES data identified de novo 
mutation in DDX3X; A second 
patient was subsequently 
identified by diagnostic WES in 
a patient with  ID 
             
18 Highly likely ARHGEF9  (X-linked)  NO   
X-linked variant does not 
segregate 
             
40 Possibly WAC/ MIB1 (de novo)  Highly likely 
WAC  
(de novo) 
In house 2nd case identified 
through diagnostic WES in 
patient with severe ID 
             
60 NO    Highly likely 
TCF4  
(de novo) 
Bioinformatic re-analysis 
identified a de novo mutation 
in TCF4 
      
 
      
72 Possibly PPP2R5D  (de novo)  Highly likely 
PPP2R5D  
(de novo) 
2nd case identified in house in 
patient with severe ID 
             
74 Possibly KIF5C  (de novo)  Highly likely 
KIF5C 
 (de novo) 
Literature reports additional 
patient with de novo mutation 
in KIF5C 
             
77 NO    Highly likely 
STXBP1 
 (de novo) 
Bioinformatic re-analysis 
identified a de novo mutation 
STXBP1   
             
85 NO    Highly likely 
SCN2A  
(de novo) 
Bioinformatic re-analysis 
identified a de novo mutation 
in SCN2A 
             
87 Possibly RAPGEF1  (de novo)  Highly likely 
MECP2  
(de novo) 
Bioinformatic re-analysis 
identified MECP2 de novo 
mutation 
      
 
      
91 Possibly EEF1A2 (de novo)  Highly likely 
EEF1A2 
(de novo) 
2nd patient in literature with 
exact same de novo mutation 
             
92 Possibly MYT1L  (de novo)  Highly likely 
MYT1L  
(de novo) 
Overlapping small CNV 
containing MYT1L described in 
literature 
             
96 NO    Highly likely 
ADNP  
(de novo) 
Bioinformatic re-analysis of 
WES data identified a de novo 
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Cohort representativeness 
Details on the clinical characteristics of all patients are provided by de Ligt et al. 201232. For the 
purpose of clarity, Table 2 provides the patient identifiers used in this study as well as the ones 
used in the previously published WES study.32 Based on the extensive clinical and diagnostic 
work-up performed for this series, including genomic microarray analysis (250K Affymetrix SNP 
microarray) as well as diagnostic exome sequencing our series represents the end point of 
current diagnostic strategies for patients with unexplained severe ID.  
 
 
Table 2: Cross-references for patient numbers used in de Ligt et al. and the current study 
 
Trio ID 
current study 
Trio ID de Ligt 
et al. 2012 
 
Trio ID current 
study 
Trio ID de Ligt 
et al. 2012 
 
Trio ID 
current study 
Trio ID de Ligt 
et al. 2012 
1 1 
 
21 37 
 
41 78 
2 4 
 
22 38 
 
42 80 
3 8 
 
23 44 
 
43 82 
4 10 
 
24 45 
 
44 86 
5 12 
 
25 46 
 
45 94 
6 17 
 
26 47 
 
46 95 
7 18 
 
27 49 
 
47 97 
8 19 
 
28 50 
 
48 98 
9 20 
 
29 51 
 
49 99 
10 21 
 
30 53 
 
50 100 
11 23 
 
31 55 
   12 24 
 
32 56 
   13 26 
 
33 57 
   14 27 
 
34 65 
   15 28 
 
35 67 
   16 30 
 
36 68 
   17 33 
 
37 71 
   18 34 
 
38 73 
   19 35 
 
39 75 
   20 36 
 
40 76 
    
Counseling and sample acquisition 
All 50 patients were part of our previous study on diagnostic exome sequencing in patients with 
severe ID and were seen and counseled by clinical specialist (MHW, BvB, TK, BBAdV or HB). This 
study was approved by the Medical Ethics Committee of the Radboud university medical center 
(NL13636.091.07; NL36191.091.11; NL19921.091.07). All participants or their legal 
representatives signed informed consent.  
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Table 3: De novo pathogenic and non-pathogenic variants previously detected using WES used to optimize de 
novo variant detection 
Trio ID Gene Genomic position (GRCh37) Protein level 
Variant 
in WGS 
data 
Identified 
as  
de novo 
mutation? 
A: Known pathogenic mutations in patients with severe ID identified using WES 
Pos. control 1 TCF4 Chr18(GRCh37):g.52896230C>T p.(Arg576Gln) + n.a. 
Pos. control 2 SCN2A Chr2(GRCh37):g.166231415G>A p.(Trp1398*) + n.a 
Pos. control 3 GRIN2B Chr12(GRCh37):g.13764781G>A p.(Pro553Leu) + n.a 
Pos. control 4 GRIN2A Chr16(GRCh37):g.9928084G>C p.(Pro522Arg) + n.a 
Pos. control 5 PDHA1 ChrX(GRCh37):g.19369435delinsAGA p.(Pro110Argfs*71) + n.a 
Pos. control 6 GATAD2B Chr1(GRCH37):g.153785737G>A p.(Gln470*) + n.a 
Pos. control 7 CTNNB1 Chr3(GRCh37):g.41275106-41275109del p.(Ser425Thrfs*11) + n.a 
Pos. control 8 LRP2 Chr2(GRCh37):g.170009333del p.(Gly4146Glufs*2) + n.a 
B: De novo mutations identified using WES2 that are not considered to be the cause of ID 
2 TRIO Chr5(GRCh37):g.14390384A>T p.(Aps1368Val) + + 
3 C15orf40 Chr15(GRCh37):g.83677401C>T p.(Ala89Thr) + + 
3 RB1 Chr13(GRCh37):g.48921977T>C p.(Tyr173His) + + 
4 CNGA3 Chr2(GRCh37):g.99012638G>T p.(Trp335Cys) + + 
4 CXXC11 Chr2(GRCh37):g.242814942G>A p.(Gly412Asp) + - 
7 CLRN3 Chr10(GRCh37):g.129690984A>T p.(Ile22Asn) + + 
7 OSBPL9 Chr1(GRCh37):g.52231512C>T p.(Pro276Leu) + + 
10 MFAP3 Chr5(GRCh37):g.153429439A>G p.(Ser53Gly) + + 
13 FHDC1 Chr4(GRCh37):g.153884006G>C p.(Leu297Phe) + + 
21 ALG13 ChrX(GRCh37):g.110928268A>G p.(Asn107Ser) + + 
21 KRT32 Chr17(GRCh37):g.39623313C>T p.(Glu89Lys) + + 
22 HADHA Chr2(GRCh37):g.26457124C>T p.(=) + + 
23 ZNF831 Chr20(GRCh37):g.57829608G>A p.(Arg1615His) + + 
29 USP8 Chr15(GRCh37):g.50790871G>A p.(=) + + 
30 NEK1 Chr4(GRCh37):g.170359295T>G p.(Lys901Asn) + -* 
36 ATP7B Chr13(GRCh37):g.52536008G>A p.(=) + + 
39 EFS Chr14(GRCh37):g.23829243G>A p.(=) + + 
40 ZFYVE16 Chr5(GRCh37):g.79733643C>T p.(Ala380Val) + + 
43 C20orf26 Chr20(GRCh37):g.20243639A>C p.(Thr790Pro) + + 
44 RBL2 Chr16(GRCh37):g.53472982G>T p.(Val99Phe) + + 
47 ABCC8 Chr11(GRCh37):g.17483205G>A p.(=) + + 
+: Identified; -: not identified; n.a.: not assessed. *Variant was detected as somatic variant in the patient after 
deep-sequencing (see also Figure 1). Trio ID refer to numbers used in this study.  
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For all genes (n=462) that remained after this selection, we subsequently interrogated 
HGMD to see how many additional patients were reported to have mutations in these 
genes. 
3. We  performed  a  systematic  literature  search  in  PubMed  using  the  search  terms  ‘Whole  
exome   sequencing’   AND   ‘Intellectual   Disability’   (23rd January 2014). This search 
returned 110 papers describing an individual gene and its relation to ID as well as 24 
studies describing multiple genes. All genes (n=154) were manually extracted from 
these publications and subsequently annotated with the number of patients reported. 
Of note, for publications describing families with autosomal recessive ID, each family 
was  counted  as  one  ‘patient’.   
4. Within the diagnostic section of our Department of Human Genetics, we routinely 
screen patient-parents trios with severe intellectual disability using exome sequencing. 
During data analysis, prioritization of (de novo) variants is based on a list of ID genes 
previously reported in patients with ID (n=494 genes). Due to the phenotypic overlap of 
ID with epilepsy and/or several metabolic disorders, this gene lists represents a wide 
spectrum of genes involved in ID. We prioritized this gene list in based on the number of 
patients  with  pathogenic  mutations  using   the   variants   from   ‘action  1’   as  well   as   from  
our in-house diagnostic and research databases collecting patients with de novo 
mutations. 
 
Based on published studies screening large patient cohorts we calculated that 1,476 patients 
were systematically screened. Including the single gene studies, we therefore estimated the 
total number of patients to be roughly 2,500. We then calculated the required number of 
patients with a de novo mutation in a single gene to achieve a 0.1/18,424 (the number of genes 
being tested) probability of a false positive. More than 90% of all 18,424 genes have a coding 
size of 3,400 bases (or less). We subsequently used this as a conservative gene size estimate. 
Applying a Poisson distribution showed that mutations in a single gene in 5 patients or more are 
required for it to be a ID gene, whereas genes with mutations in one or more but less than 5 
patients were used as candidate ID gene.  
 
Table 4: Classification of genes according to the frequency of reported pathogenic mutations 
 
Total genes Known ID gene Candidate ID gene 
HGMD with phenotype ID or MR 368 347 21 
PubMed  search  ‘WES+ID’ 154 102 52 
Diagnostic gene list 494 407 87 
Large-scale sequencing studies with     
          overlapping phenotypes 462 77 385 
Total unique genes  528 628 
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17.68, P < 1.0E-06; Median Ns/Ss = 1.5, P<1.0E-06) as well as in candidate ID genes (Median 
Ns/Kb = 17.61, P<1.0E-06; Median Ns/Ss = 1.545, P<1.0E-06), whereas we found a significantly 
higher tolerance in loss-of-function tolerant genes (Median Ns/Kb = 26.49, P<1.0E-06; Median 
Ns/Ss = 2.214, P<1.0E-06) (Extended Data Figure 1). 
 
We repeated this analysis for the 9 known and 10 candidate ID genes in which we found de 
novo mutations in our patients. These analyses showed a significant lower tolerance for rare 
missense variants for the 9 known ID genes (Median Ns/Kb = 9.45, P = 0.0017; Median Ns/Ss = 
0.71, P=2.03E-04) as well as for the 10 candidate ID genes (Median Ns/Kb = 12.8, P = 0.013; 
Median Ns/Ss = 1.27, P=0.037). P-values   from   both   scores   were   combined   using   Fisher’s  
combined probability test. 
 
Statistical analysis for overrepresentation of deleterious mutations in patients 
with severe ID 
We compared the proportion of de novo loss-of-function (LoF) mutations (n=18, including 
nonsense, frameshift and canonical splice site) identified in our cohort to frequencies reported 
in healthy controls from multiple published studies (Table 5).45,47,49-51,53 To test significance, we 
used a two-sided  Fisher’s  exact  test  as  implemented  in  R.29 
Overrepresentation of de novo mutations 
Overrepresentation of de novo mutations in known and candidate ID gene lists was calculated 
by first calculating the total coding size in the genome based on refSeq annotation (32,342,354) 
and comparing the coding de novo rate to the coding de novo rate within the coding sequence 
 
 Table 5: Overview of de novo mutations in healthy individuals 
 Number of controls 
(c) or siblings (s) 
Total LoF Missense Synonymous 
Rauch et al. 20 (c) 24 2 15 7 
O'Roak et al. 50 (s) 29 1 19 9 
Sanders et al.* 200 (s) 125 5 82 38 
Iossifov et al.** 343 (s) 288 12 203 73 
Gulsuner et al. 84 (c) 67 12 36 19 
Xu et al.*** 34 (c) 16 0 11 5 
Total 731 549 32 366 151 
Putative LoF includes nonsense, frameshift and canonical splice site mutations based on gene 
annotation; * study did not consider indels; ** not all de novo mutations were validated by 
Sanger sequencing; ***excluded splice site variants if not in canonical di-nucleotide of splice site. 
For some studies the numbers deviate from the numbers given in the main publication, numbers 
considered here were retrieved from de novo mutation overviews from supplementary tables. 
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individuals. To test this hypothesis, we systematically analysed reported de novo mutations in 
controls and unaffected sibs.45,47,49-51,53 Together, these studies reported 566 de novo mutations 
in 731 healthy individuals, from which we subsequently selected those mutations that were 
validated by Sanger sequencing. The remaining set, totaling 203 de novo mutations, were 
evaluated according to the diagnostic criteria. Six de novo  (2.9%) mutations affected dominant 
disease genes, including 5 genes from the known and 1 from the candidate ID gene list 
respectively (Table 6). In a clinical diagnostic setting these mutations would be examined with 
respect to the known molecular mechanism of disease. This shows that most of these 
mutations are unlikely to cause ID or autism. For instance, DIP2B is associated with a severe ID 
phenotype but is caused by repeat expansion rather than point mutations, hence, a de novo 
missense mutation (as identified in a control) is unlikely to result in the same phenotype, if any 
at all. 
 
Table 6: De novo mutations in dominant ID genes in control individuals 
chr genomic position 
Mutation 
type Ref Mut Gene Protein change PhyloP 
known or 
candidate ID 
gene 
chr12 51090925 Missense C T DIP2B p.Thr672Met 4.27 candidate 
chr17 29684348 Missense C T NF1 p.Ala2623Val 5.50 known 
chr5 176715871 Missense C G NSD1 p.Thr2068Ser 6.08 known 
chr10 123260408 Missense G A FGFR2 p.Ala498Val 6.22 known 
chr17 17697260 inframe insertion - AGT RAI1 p.Gln333_Tyr334insVal - known 
chr12 13716876 frameshift CG N GRIN2B p.Arg1099fs - known 
 
Next, as part of the regular diagnostic process, the phenotype of the disease is analyzed to see 
whether it would match the patient’s description. Three genes, NF1 (Neurofibromatosis), NSD1 
(Sotos Syndrome) and FGFR2 (Crouzon syndrome), cause dominant diseases in which severe ID 
or autism is only present in a small minority of patients. Moreover, if present, the level of ID is 
generally less severe. Other clinical features should be sought in these patients such as Café au 
lait spots (NF1), tall stature and macrocephaly (NSD1), and skull abnormalities (FGFR2) in a 
diagnostic setting, but we should not expect these mutations to frequently result in either 
severe ID or autism. This leaves the mutations in RAI1 and in GRIN2B as the only 2 examples 
that would be likely to be called pathogenic in a diagnostic setting in these published series of 
731 individuals included as controls for severe ID or autism. 
 
However, we note that all disease causing mutations in RAI1 reported sofar are loss-of-function 
mutations. For an in frame insertion, as seen for RAI1 (Smith Magenis Syndrome), it is difficult 
to predict its effect. A frameshift mutation in GRIN2B (MRD6), is clearly expected to result in ID. 
Given that the GRIN2B mutation is expected to result in epilepsy, re-phenotyping of this 
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Table 7: Calculation of de novo mutations as cause of severe ID 
    Diagnostic yield                            
in cohort 
Estimated                                  
cumulative percentage     
Genomic microarray 
    (n=1,489 patients with severe ID) 
  De novo dominant cause by CNV (n=173) 11.60% 11.60% 
Whole Exome Sequencing  
    (n=100 array negative patients) 
  De novo dominant cause by SNV (n=25)  25.00% 22.10% 
  De novo dominant cause by CNV  (n=1)  1.00% 0.88% 
  Recessive cause by SNV (n=1)  1.00% 0.88% 
Whole Genome Sequencing  
    (n=50 WES negative patients) 
  De novo dominant cause by SNV (n=13)  26.00% 16.77% 
  De novo dominant cause by CNV  (n=7)  14.00% 8.39% 
  Recessive cause by SNV (n=1)  2.00% 1.29% 
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Supplementary Table 2: Average genome sequencing statistics per individual 
 
Genome Average  
Fully called genome fraction 0.98 
  No-called called genome fraction 0.02 
  Reference genome fraction of bases with coverage >= 40x 0.92 
      
Total number of called single nucleotide substitution variants 3,509,927 
Total number of called insertion variants 384,487 
Total number of called deletion variants 375,832 
Total number of complex single nucleotide variants 176,009 
      
Total CNV segment count 276 
   Exome*  Average  
Fully called exome fraction 0.99 
  No-called exome fraction 0.01 
  Exome fraction of bases with coverage >= 40x 0.94 
      
Total number of single nucleotide substitution variants 22,186 
  Synonymous SNV loci 10,744 
  Non-synonymous SNV loci 10,081 
    Missense  9,966 
    Nonsense  84 
    Disruption stop codon 12 
    Disruption initiation codon 20 
    Block substitutions 77 
      
Total number of  insertion variants 590 
Total number of deletion variants 484 
Total number of complex single nucleotide variants 1,243 
 
Sequencing statistics as supplied by Complete Genomics.  Genome fractions are based on the GRCh37 reference 
genome. Number of variants represent unfiltered total calls as made by Complete Genomics. Functional annotation 
of SNVs is based on RefSeq annotation by Complete Genomics. *‘Exome’  as  defined  by Complete Genomics. 
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Supplementary Table 3: Comparison of variants between WES and WGS identified in regions 
targeted by exome enrichment kit 
 
 
Overlap for WGS and WES  Average 
(150 samples)  SD 
Total number of variants 16,964  1,716 
    Insertions/Deletions 843  110 
    In regions with high WES coverage  1,392  1,018 
    In regions with low WES coverage  1,219  319 
Variants in coding sequence 10,812  975 
  
   
Whole Genome Sequencing only Average 
(150 samples)  SD 
Total number of variants 28,028  2,187 
    Insertions/Deletions 2,579  168 
    In regions with high WES coverage  1,450  835 
    In regions with low WES coverage  10,480  1,633 
Variants in coding sequence 11,333  1,186 
  
   
Whole Exome Sequencing only Average 
(150 samples)  SD 
Total number of variants 1,213  123 
    Insertions/Deletions 94  18 
    In regions with high WES coverage  357  92 
    In regions with low WES coverage  60  18 
Variants in coding sequence 622  64 
 
Comparison between variants called by genome sequencing and exome sequencing within the targets of the 
Agilent 50Mb exome enrichment kit (v2). Variants called exclusively by genome sequencing tended to lie in regions 
with very low exome coverage, whereas variants called exclusively by exome sequencing tended to lie in regions of 
very high exome coverage. This latter is likely due to mapping issues in repeat regions. Note, regions of very high 
exome coverage are defined as regions of at least three times the median exome coverage. Regions of very low 
exome coverage are regions with less than one third of the median exome coverage. 
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Supplementary Table 4: Overview of putative de novo SNVs detected through WGS 
  High confidence  Medium confidence  Low confidence 
  Sum Min Max Median  Sum Min Max Median  Sum Min Max Median 
Total  4,081 47 111 82  5,034 68 142 98.5  62,622 909 1,500 1,279 
Exonic  80 0 5 1  82 0 5 1  670 6 23 14 
  Missense 51 0 1 1  49 0 0 1  360 5 0 10 
  Synonymous 21 0 2 0  21 0 2 0  189 1 10 3 
  Nonsense 8 0 2 0  3 0 1 0  20 0 3 0 
  In-frame insertions 0 0 0 0  1 0 1 0  5 0 1 0 
  In-frame deletions 0 0 0 0  1 0 1 0  8 0 1 0 
  In-frame complex 0 0 0 0  0 0 0 0  1 0 1 0 
  Out-of-frame insertions 0 0 0 0  0 0 0 0  67 0 5 1 
  Out-of-frame deletions 0 0 0 0  4 0 1 0  18 0 2 0 
  Out-of-frame complex 0 0 0 0  0 0 0 0  2 0 1 0 
Splice sites 6 0 1 0  6 0 1 0  72 0 5 1 
  SA canonical 1 0 1 0  1 0 1 0  4 0 1 0 
  SD canonical 0 0 0 0  1 0 0 0  4 0 1 0 
  SA 4 0 1 0  3 0 1 0  50 0 4 1 
  SD 1 0 1 0  1 0 0 0  14 0 3 0 
Intronic  1,382 13 42 26.5  1,558 17 57 30.5  19,202 288 504 376 
  of known ID genes 34 0 4 0  n.a n.a n.a n.a  n.a n.a n.a n.a 
UTR  193 0 11 3.5  206 0 13 4  2525 7 82 61.5 
  of known ID genes 6 0 2 0  n.a n.a n.a n.a  n.a n.a n.a n.a 
MicroRNA 0 0 0 0  1 0 1 0  2 0 1 0 
Non-genic 2,422 31 69 48  3,184 41 90 63  40,151 590 964 813.5 
 
Statistics of de novo mutations identified across 50 trios. De novo calls were categorized in three confidences (see supplementary methods). Top row column header 
indicates the confidence category; second row column header indicates for each category the total number, the minimum number,  the maximum number and the median of 
variants identified across all 50 trios. Rows indicate functional categorization of variants based on their location in the genome. Splice sites are divided into splice acceptor 
(SA) and splice acceptor (SD) canonical, being the first two bases into the intron as well as the complete splice acceptor being 20 bp within the intron and the complete splice 
donor, 8 bp within the intron. 
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Supplementary Table 5: Validation rates of autosomal candidate de novo SNVs grouped by 
genomic location and confidence level 
 
 Confidence 
   
 Low Medium High 
 Total  
Coding 4/139  17/82 59/80  80/301 
(27%) 
 
Splice sites* 0/15 1/6 4/6  5/27 
(19%) 
 
Intronic n.a. n.a. 42/46  42/46 
(91%) 
 
UTR n.a. n.a. 3/7  3/7 
(42%) 
 
Promoter n.a. n.a. 1/1  1/1 
(100%) 
 
      
 
Total 4/154 
(3%) 
18/88 
(20%) 
109/140 
(78%)  
131/382 
(34%) 
 
n.a. = not assessed. *includes canonical splice sites. 
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Supplementary Table 6: Distribution of de novo SNVs in coding sequence identified through 
WGS 
 
 
Number of 
patients (WGS) 
Mutation Negative 9 
    0 mutations 9 
 
 
Mutation Positive 41 
  1 mutation 15 
  2 mutations 14 
  3 mutations 8 
  4 mutations 3 
  5 mutations 1 
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Supplementary Table 7: De novo substitution rates and type of mutations identified 
through WGS  
 
 
Number of mutations 
 WGS 
Synonymous 19 
  Predicted effect on splicing 4 
  No predicted effect on splicing 15 
    
Non-synonymous 65 
  Nonsense 10 
  Missense 49 
  Insertion/deletion 5 
  Canonical splice site 1 
    
De novo mutation rate* 1.58 
 
 
*Calculation of the de novo mutation rate is based on substitutions only.  
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Supplementary Table 8: Coding de novo SNVs identified in 50 patients with severe ID  
 
Trio Gene Genomic annotation cDNA Protein 
Mutation 
type 
predicted 
effect on 
splicing?# 
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Diagnostic 
interpretation 
of individual 
variants 
1 NGFR Chr17(GRCh37):g.47583816T>C NM_002507.3:c.364T>C p.Cys122Arg Missense -   F  P C B G M  Candidate 
2 GFPT2 Chr5(GRCh37):g.179728574G>C NM_005110.2:c.2039C>G p.Thr680Ser Missense -   F  P C B G   Candidate 
2 TRIO Chr5(GRCh37):g.14390384A>T NM_007118.2:c.4103A>T p.Asp1368Val Missense -  K
# F    B G M  NO* 
3 C15orf40 Chr15(GRCh37):g.83677401C>T NM_001160115.1:c.265G>A p.Ala89Thr Missense -     P      NO 
3 RB1 Chr13(GRCh37):g.48921977T>C NM_000321.2:c.517T>C p.Tyr173His Missense -     P  B G M  NO 
3 SSPO Chr7(GRCh37):g.149487581G>T NM_198455:c.4895G>T p.Gly1632Val Missense -   F        NO 
3 USP42 Chr7(GRCh37):g.6196670C>G NM_032172.2:c.3927C>G p.Leu1309Leu Synonymous -       u  M  NO 
4 CNGA3 Chr2(GRCh37):g.99012638G>T NM_001298.2:c.1005G>T p.Trp335Cys Missense -     P C B G M  NO 
4 CXXC11 Chr2(GRCh37):g.242814942G>A NM_173821.2:c.1235G>A p.Gly412Asp Missense -     P  B    NO 
4 LPPR3 Chr19(GRCh37):g.815253C>T NM_024888.1:c.336G>A p.Ala112Ala Synonymous no   F    u    NO 
6 CDC5L Chr6(GRCh37):g.44392245C>T NM_001253.2:c.1494C>T p.Ala498Ala Synonymous no       B    NO 
6 POP1 Chr8(GRCh37):g.99142350C>T NM_001145860.1:c.631C>T p.Arg211Trp Missense -   F  P      NO 
6 WWP2 Chr16(GRCh37):g.69820943A>T NM_007014.3:c.30A>T p.Gly10Gly Synonymous possibly   F D   B G   Candidate 
7 CLRN3 Chr10(GRCh37):g.129690984A>T NM_152311.3:c.65T>A p.Ile22Asn Missense -     P      NO 
7 OSBPL9 Chr1(GRCh37):g.52231512C>T NM_148909.3:c.827C>T p.Pro276Leu Missense -     P C B    NO 
7 OTX2 Chr14(GRCh37):g.57268586G>T NM_021728.2:c.761C>A p.Ser254* Nonsense -   F D   B G M  NO** 
7 TBR1 Chr2(GRCh37):g.162275551A>G NM_006593.2:c.1118A>G p.Gln373Arg Missense -  K F  P C B G M  Known 
7 YTHDC1 Chr4(GRCh37):g.69203353T>C NM_001031732.2:c.396A>G p.Lys132Lys Synonymous no       B    NO 
8 CNOT1 Chr16(GRCh37):g.58564225C>A NM_016284.3:c.6204G>T p.Leu2068Leu Synonymous no  K
#     B G   NO* 
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Supplementary Table 8: Coding de novo SNVs identified in 50 patients with severe ID  
 
Trio Gene Genomic annotation cDNA Protein 
Mutation 
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predicted 
effect on 
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Diagnostic 
interpretation 
of individual 
variants 
1 NGFR Chr17(GRCh37):g.47583816T>C NM_002507.3:c.364T>C p.Cys122Arg Missense -   F  P C B G M  Candidate 
2 GFPT2 Chr5(GRCh37):g.179728574G>C NM_005110.2:c.2039 >G p.Thr680Ser Missense -   F  P C B G   Candidate 
2 TRIO Chr5(GRCh37):g.14390384A>T NM_007118.2:c.4103A>T p.Asp 368Val Missense -  K
# F    B G M  NO* 
3 C15orf40 Chr15(GRCh37):g.83677401C>T NM_00 160115.1:c.265G>A p.Ala89Thr Missense -     P      NO 
3 RB1 Chr13(GRCh37):g.48921977T>C NM_000321.2:c.5 7T>C p.Tyr173His Missense -     P  B G M  NO 
3 SSPO Chr7(GRCh37):g.14948758 G>T NM_198 55:c.4895G>T p.Gly1632Val Missense -   F        NO 
3 USP42 Chr7(GRCh37):g.6196670C>G NM_032172.2:c.3927C>G p.Leu1309Leu Synonymous -       u  M  NO 
4 CNGA3 Chr2(GRCh37):g.99012638G>T NM_0012 8.2:c.1005G>T p.Trp335Cys Missense -     P C B G M  NO 
4 CXXC11 Chr2(GRCh37):g.242814942G>A NM_17382 .2:c.1235G>A p.Gly412Asp Missense -     P  B    NO 
4 LPPR3 Chr19(GRCh37):g.815253C>T NM_02488 .1:c.336G>A p.Ala112Ala Synonymous no   F    u    NO 
6 CDC5L Chr6(GRCh37):g.44392245C>T NM_001253.2:c.1494C>T p.Ala498Ala Synonymous no       B    NO 
6 POP1 Chr8(GRCh37):g.99142350 >T NM_001145860.1:c.631C>T p.Arg 11Trp Missense -   F  P      NO 
6 WWP2 Chr16(GRCh37):g.69820943A>T NM_0070 .3:c.30A>T p.Gly10Gly Synonymous ossibly   F D   B G   Candidate 
7 CLRN3 Chr10(GRCh37):g.129690984A>T NM_152311.3:c.65T A p.Ile22Asn Missense -     P      NO 
7 OSBPL9 Chr1(GRCh37):g.52231512C>T NM_14890 .3:c.827C  p.Pro276Leu Missense -     P C B    NO 
7 OTX2 Chr14(GRCh37):g.57268586G>T NM_0217 8.2:c.761C>A p.Ser254* Nonsense -   F D   B G M  NO** 
7 TBR1 Chr2(GRCh37):g.162275551A>G NM_006 93.2:c.1118A>G p.Gln373Arg Missense -  K F  P C B G M  Known 
7 YTHDC1 Chr4(GRCh37):g.69203353T>C NM_00 031 32.2:c.396A>G p.Lys132Lys Synonymous no       B    NO 
8 CNOT1 Chr16(GRCh37):g.58564225C>A NM_01 284.3:c.6204G>T p.Leu2068Leu Synonymous no  K
#     B G   NO* 
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9 CARD8 Chr19(GRCh37):g.48734215G>A NM_001184900.1:c.591C>T p.Leu197Leu Synonymous no       B    NO 
9 ELP2 Chr18(GRCh37):g.33713240C>T NM_018255.1:c.178C>T p.Arg60* Nonsense -  K
# F D   B    NO*** 
9 WDR45 ChrX(GRCh37):g.48932518del NM_007075.3:c.1030del p.Cys344Alafs*67 Frameshift -  K F D   B    Known 
10 LIPI Chr21(GRCh37):g.15535845C>T NM_198996.2:c.965-1G>A - Splice site possibly        G M  NO 
10 MFAP3 Chr5(GRCh37):g.153429439A>G NM_005927.4:c.157A>G p.Ser53Gly Missense -       B    NO 
13 FHDC1 Chr4(GRCh37):g.153884006G>C NM_033393.2:c.891G>C p.Leu297Phe Missense -   F  P  B    NO 
13 FHOD1 Chr16(GRCh37):g.67281195G>A NM_013241.2:c.119C>T p.Ala40Val Missense -      C     NO 
13 SMC1A ChrX(GRCh37):g.53430554del NM_006306.2:c.2364del p.Asn788Lysfs*10 Frameshift -  K F D   B G M  Known 
13 ZNF566 Chr19(GRCh37):g.36940271C>T NM_001145345.1:c.865G>A p.Gly289Arg Missense -     P C B    NO 
14 GPR52 Chr1(GRCh37):g.174417259T>G NM_005684.4:c.10T>G p.Ser4Ala Missense -       B    NO 
15 DSP Chr6(GRCh37):g.7583973C>T NM_004415.2:c.6478C>T p.Arg2160* Nonsense -    D     M  NO 
15 PTPN21 Chr14(GRCh37):g.88945321C>T NM_007039.3:c.2454G>A p.Pro818Pro Synonymous no           NO 
15 SPTAN1 Chr9(GRCh37):g.131331084G>A NM_001130438.2:c.271G>A p.Glu91Lys Missense -  K F  P C B G M  Known 
17 ASUN Chr12(GRCh37):g.27087494G>A NM_018164.2:c.295C>T p.Gln99* Nonsense -   F D   B    Candidate 
17 PI4K2B Chr4(GRCh37):g.25236025G>C NM_018323.3:c.240G>C p.Glu80Asp Missense -           NO 
19 TBKBP1 Chr17(GRCh37):g.45786784A>C NM_014726.2:c.1685A>C p.His562Pro Missense -       B    NO 
20 SON Chr21(GRCh37):g.34923418_34923419del NM_138927.1:c.1881_1882del p.Val629Alafs*56 Frameshift -   F D   B  u  NO 
21 ALG13 ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Missense  -  K
# F  P  B G M  Known**** 
21 CBLB Chr3(GRCh37):g.105421227G>A NM_170662.3:c.1670C>T p.Pro557Leu Missense  -     P C B  M  NO 
21 KRT32 Chr17(GRCh37):g.39623313C>T NM_002278.3:c.265G>A p.Glu89Lys Missense  -     P      NO 
21 RAI1 Chr17(GRCh37):g.17696524C>T NM_030665.3:c.262C>T p.Gln88* Nonsense  -  K F D   B G M  Known 
22 HADHA Chr2(GRCh37):g.26457124C>T NM_000182.4:c.414G>A p.Val138Val Synonymous no       B G M  NO 
22 MED13L Chr12(GRCh37):g.116435026T>C NM_015335.4:c.2579A>G p.Asp860Gly Missense  -  K
# F  P C B    Known 
23 POLQ Chr3(GRCh37):g.121208286C>T NM_199420.3:c.3492G>A p.Glu1164Glu Synonymous no           NO 
23 ZNF831 Chr20(GRCh37):g.57829608G>A NM_178457.1:c.4844G>A p.Arg1615His Missense -     P  u    NO 
24 BRD3 Chr9(GRCh37):g.136913290A>G NM_007371.3:c.1001T>C p.Phe334Ser Missense -   F  P C B    Candidate 
24 SEZ6 Chr17(GRCh37):g.27286180C>T NM_178860.4:c.1970G>A p.Arg657Gln Missense possibly   F    B G M  NO 
24 TNIP3 Chr4(GRCh37):g.122078277A>G NM_001128843.1:c.335T>C p.Leu112Pro Missense  -           NO 
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25 SATB2 Chr2(GRCh37):g.200213667_200213668ins GTTGCCTTACAA 
NM_001172517.1:c.929_930insTTGTA
AGGCAAC 
p.Gln310delinsHis 
CysLys AlaThr Insertion no  K F D  C B G M  Known 
26 ELMO2 Chr20(GRCh37):g.45022193C>A NM_133171.3:c.167G>T p.Gly56Val Missense -     P C B    NO 
26 PPP2R5D Chr6(GRCh37):g.42975030T>A NM_006245.2:c.619T>A p.Trp207Arg Missense -  K
# F  P C B G M  Known 
27 CATSPERB Chr14(GRCh37):g.92136238G>T NM_024764.2:c.1207C>A p.Arg403Arg Synonymous possibly           NO 
27 KCNA1 Chr12(GRCh37):g.5021656C>T NM_000217.2:c.1112C>T p.Thr371Ile Missense -  K F  P C B G M  Known 
27 SPACA7 Chr13(GRCh37):g.113030776C>T NM_145248.4:c.77C>T p.Pro26Leu Missense -       u    NO 
28 DOK4 Chr16(GRCh37):g.57513380C>A NM_018110.3:c.40G>T p.Val14Leu Missense -   F   C B G   NO 
28 SCN2A Chr2(GRCh37):g.166243265C>T NM_001040142.1:c.4561C>T p.Gln1521* Nonsense -  K F D   B G M  Known 
29 USP8 Chr15(GRCh37):g.50790871G>A NM_001128611.1:c.3117G>A p.Gln1039Gln Synonymous no       B    NO 
30 MAST1 Chr19(GRCh37):g.12984501C>G NM_014975.2:c.3530C>G p.Pro1177Arg Missense -   F  P C B G   Candidate 
30 NEK1 Chr4(GRCh37):g.170359295T>G NM_001199397.1:c.2703A>C p.Lys901Asn Missense -       B  M  NO 
32 PNLIPRP1 Chr10(GRCh37):g.118354347C>T NM_006229.2:c.436C>T p.Gln146* Nonsense -    D    G   NO 
33 CDC34 Chr19(GRCh37):g.541442G>A NM_004359.1:c.601G>A p.Glu201Lys Missense -   F    B    NO 
33 FAM46B Chr1(GRCh37):g.27339042G>A NM_052943.3:c.120C>T p.Ala40Ala Synonymous no   -        NO 
34 APPL2 Chr12(GRCh37):g.105591609G>C NM_018171.3:c.986C>G p.Ser329* Nonsense -   F D   B G M  Candidate 
34 SMAD6 Chr15(GRCh37):g.66995638G>A NM_005585.4:c.42G>A p.Trp14* Nonsense -    D     M  NO 
34 ZNF423 Chr16(GRCh37):g.49670125T>C NM_015069.3:c.2938A>G p.Thr980Ala Missense    F    B    NO 
36 ATP7B Chr13(GRCh37):g.52536008G>A NM_000053.3:c.1911C>T p.Asn637Asn Synonymous no       B G M  NO 
36 CEP170B Chr14(GRCh37):g.105352391G>C NM_001112726.2:c.1959G>C p.Pro653Pro Synonymous no       u    NO 
37 PIAS1 Chr15(GRCh37):g.68468014T>A NM_016166.1:c.1209T>A p.Asp403Glu Missense -  K
# F    u G   NO* 
38 GIPC2 Chr1(GRCh37):g.78511993G>T NM_017655.4:c.215G>T p.Gly72Val Missense -           NO 
39 EFS Chr14(GRCh37):g.23829243G>A NM_005864.2:c.444C>T p.Tyr148Tyr Synonymous no       B    NO 
40 ZFYVE16 Chr5(GRCh37):g.79733643C>T NM_014733.3:c.1139C>T p.Ala380Val Missense no       B G   NO 
41 CLSTN3 Chr12(GRCh37):g.7295875C>T NM_014718.3:c.1815C>T p.Gly605Gly Synonymous no   F    B    NO 
41 NACC1 Chr19(GRCh37):g.13249038C>T NM_052876.2:c.1402C>T p.Arg468Cys Missense -   F   C B    Candidate 
42 HIVEP2 Chr6(GRCh37):g.143092683C>T NM_006734.3:c.3193G>A p.Ala1065Thr Missense -  K
# F    B    NO* 
43 C20orf26 Chr20(GRCh37):g.20243639A>C NM_015585.3:c.2368A>C p.Thr790Pro Missense -     P C B    NO 
43 EYA4 Chr6(GRCh37):g.133777699C>G NM_004100.4:c.283C>G p.Leu95Val Missense -  K
#    C   M  NO* 
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K: Known ID gene; K#: Candidate ID gene; F: Functional link to ID; D: deleterious mutation; P: Predicted pathogenic mutation; C: Conserved genomic location (not assessed for 
deleterious mutations); B: Brain expressed; G: Annotated with GO BP terms that are enriched in known ID genes; M: Annotated with mouse phenotypes that are enriched in 
known ID genes.*Despite being a mutation in a candidate ID gene, this mutation is not considered the cause of ID as the mutation impact on protein function is not 
(predicted) pathogenic.  **: the OTX2 mutation in this patient is not diagnostically reported as cause of ID due to the classical phenotype for OTX2 mutations not being 
observed (ocular anomalies and pituitary deficiency). Alternatively, the phenotypic consequences of the OTX2 mutation in this patient may be atypic and superseded by the 
de novo TBR1 mutation. ***ELP2 mutations are known for autosomal recessive ID.77 In this patient, no second (inherited) pathogenic mutation was encountered, suggesting 
that this mutation creates a carrier ship rather than a cause for disease. This explanation is further supported by the fact that the patient has a pathogenic mutation in 
WDR45, fully explaining the patients phenotype. ****: Additional ALG13 mutations have been reported in patients with ID since selection of this patient cohort.46,78; In 
retrospect, this mutation may have clinical consequences. Nonetheless, a nonsense mutation in RAI1 has been identified in the same patient during this study, which 
seemingly explains the full phenotype of the patient. Alternatively, the phenotype due to the ALG13 mutation may be merged into the RAI1 phenotype, making it impossible 
to distinguish which part of the phenotype is caused by which mutation. This phenomenon, that two (de novo) pathogenic mutations are  identified in a single patient has 
been described before.79 
43 POGZ Chr1(GRCh37):g.151378510G>A NM_015100.3:c.3001C>T p.Arg1001* Nonsense -  K
# F D   B    Known 
44 RBL2 Chr16(GRCh37):g.53472982G>T NM_005611.3:c.295G>T p.Val99Phe Missense -     P  B  M  NO 
46 CREBL2 Chr12(GRCh37):g.12788868G>C NM_001310.2:c.173G>C p.Arg58Pro Missense -     P  B G   NO 
46 TBR1 Chr2(GRCh37):g.162280277_162280283dup NM_006593.2:c.1588_1594dup p.Thr532Argfs*144 Frameshift -  K F D   B G M  Known 
47 ABCC8 Chr11(GRCh37):g.17483205G>A NM_000352.3:c.747C>T p.Ala249Ala Synonymous no       B G   NO 
48 EPHB1 Chr3(GRCh37):g.134514481T>G NM_004441.4:c.8T>G p.Leu3Arg Missense -   F    B G M  NO 
48 UCP1 Chr4(GRCh37):g.141489817C>T NM_021833.4:c.67G>A p.Ala23Thr Missense -        G M  NO 
49 ERV3-1 Chr7(GRCh37):g.64452368A>C NM_001007253.3:c.1037T>G p.Ile346Ser Missense -       B    NO 
49 KANSL2 Chr12(GRCh37):g.49072911C>A NM_017822.3:c.453G>T p.Gly151Gly Synonymous possibly  K
# F D  C u    Known 
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Supplementary Table 9: Coding de novo mutation rates of published studies 
 
Study Number of individuals 
Patients/ 
Controls DIsease* 
# de novo 
SNVs excl 
indels 
# de novo 
SNVs incl 
indels 
Coding mutation 
rate SNVs  
excl indels 
Coding mutation 
rate SNVs  
incl indels 
This study 50 Patients ID 79 84 1.58 1.68 
Rauch et al. 32 51 Patients ID 72 85 1.41 1.67 
O'Roak et al.33 189 Patients ASD 225 242 1.19 1.28 
Epi4K46 264 Patients EE 309 329 1.17 1.25 
Jiang et al.34 32 Patients ASD 36 38 1.13 1.19 
Rauch et al.32 20 Controls - 22 23 1.10 1.15 
Neale et al.17 175 Patients ASD 161 167 0.92 0.95 
Gulsuner et al.51 105 Patients SCHZ 96 103 0.91 0.98 
Iossifov et al.31 343 Patients ASD 305 305 0.89 0.89 
Iossifov et al.31 343 Controls - 294 294 0.86 0.86 
Gulsuner et al.51 84 Controls - 66 67 0.79 0.80 
de Ligt et al.2 100 Patients ID 72 79 0.72 0.79 
Sanders et al.30 238 Patients ASD 164 167 0.69 0.70 
Xu et al.53 53 Patients SCHZ 36 40 0.68 0.75 
Sanders et al.30 200 Controls - 125 125 0.63 0.63 
Xu et al.53 22 Controls - 8 8 0.36 0.36 
*: ID: Intellectual Disability; EE: Epileptic Encephalopathies; SCHZ: Schizophrenia; ASD: Autism Spectrum 
Disorder 
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Supplementary Table 10: List of 528 known ID genes used for prioritization of variants 
Gene 
ABCC9 ASXL1 CHD7 ERCC5 GPC3 KIF11 MTR PAFAH1B1 PYCR1 SLC35C1 TNK2 
ABCD1 ATP1A2 CHKB ERCC6 GPHN KIF7 MTRR PAK3 RAB18 SLC4A4 TOR1A 
ABCD4 ATP2A2 CHRND ERCC8 GPR56 KIRREL3 MUT PANK2 RAB27A SLC6A3 TPK1 
ABHD5 ATP6V0A2 CLCN7 ESCO2 GRIA3 KIT MVK PARP1 RAB3GAP1 SLC6A8 TPO 
ACAD9 ATP7A CLN8 ETFB GRIN2A KNCQ2 MYCN PAX6 RAB3GAP2 SLC7A7 TRAPPC9 
ACOX1 ATR CNTNAP2 ETHE1 GRIN2B KRAS MYH9 PC RAF1 SLC9A6 TREX1 
ACSF3 ATRX COG8 EXOSC3 GRM1 L1CAM MYO1E PCDH19 RAI1 SMAD4 TRIM32 
ACTB ATXN1 COL4A1 EXT1 GSS L2HGDH MYO3A PCNT RARS2 SMARCA2 TRPM6 
ACTG1 AUH COL4A2 FAM123B GUSB LAMA2 MYT1L PDE4D RASGEF1B SMARCA4 TSC1 
ACVR1 AUTS2 COLEC11 FANCB HAX1 LAMC3 NAGA PDHA1 RBFOX1 SMARCB1 TSC2 
ADAR B3GALTL COQ2 FANCD2 HCCS LAMP2 NAGLU PEPD RFT1 SMARCE1 TSPAN7 
ADCK3 BBS1 CREBBP FBN1 HCFC1 LARGE NBN PEX1 RFX3 SMC1A TTC8 
ADSL BBS10 CTNNB1 FGD1 HDAC4 LCT NDE1 PEX10 RNASEH2A SMOC1 TTN 
AFF2 BBS12 CUBN FGFR2 HDAC8 LIG4 NDP PEX13 RNASEH2B SMPD1 TUBA1A 
AGA BBS2 CUL3 FGFR3 HESX1 LRP1 NDUFS1 PEX26 RNASEH2C SMS TUBB2B 
AGPAT2 BBS4 CUL4B FH HLCS LRP2 NDUFS2 PEX5 ROGDI SNAP29 TUSC3 
AGTR2 BBS5 CYB5R3 FKRP HMGA2 MAN2B1 NDUFS4 PEX7 RP2 SOS1 TWIST1 
AHCY BBS7 D2HGDH FKTN HNRNPU MANBA NDUFS8 PGAP2 RPGRIP1L SOX10 UBE2A 
AHI1 BBS9 DARS2 FLG HOXA1 MAP2K1 NDUFV1 PGK1 RPS6KA3 SOX2 UBE3A 
AK1 BCKDHA DBT FLNA HPD MAP2K2 NEDD4L PHF21A RTEL1 SOX3 UBR1 
AKT3 BCKDHB DCX FMR1 HPRT1 MAPT NEU1 PHF6 RUNX1 SOX5 UPB1 
ALDH18A1 BCOR DDHD2 FOXG1 HRAS MAT1A NF1 PHF8 RYR1 SPG7 UPF3B 
ALDH3A2 BCS1L DHCR24 FOXP1 HSD17B10 MBD5 NFIA PHGDH RYR2 SPRED1 VLDLR 
ALDH5A1 BLM DHCR7 FOXP2 HUWE1 MBTPS2 NFIX PIGV SALL1 SPTAN1 VPS13B 
ALG1 BRAF DISC1 FRAS1 IDS MCCC1 NHS PLCB1 SATB2 SRCAP VPS39 
ALG12 BSCL2 DKC1 FTO IDUA MCCC2 NIPBL PLP1 SBF1 SRD5A3 WDR11 
ALG3 BUB1B DLD FTSJ1 IFT172 MCOLN1 NKX2-1 PMM2 SCN1A SRGAP3 WDR19 
ALG6 C5ORF42 DLG3 FUCA1 IGF1 MCPH1 NLGN1 PNKP SCN2A STRA6 WDR45 
AMT C7orf11 DMD GABRA1 IKBKG MECP2 NLGN4X PNP SCN8A STS WDR62 
ANK2 CA2 DNAH5 GABRB3 IL1RAPL1 mecp2e1 NLRP3 POLG SCO2 STXBP1 XPA 
ANK3 CACNA1A DNMT3B GALE INPP5E MED12 NOG POLR3A SDHA SUCLA2 YWHAE 
ANKH CACNA1C DOCK8 GALT IQSEC2 MEF2C NOTCH3 POLR3B SERAC1 SUOX ZDHHC9 
ANKRD11 CASK DPAGT1 GAMT IRS1 MGAT2 NPHP1 POMGNT1 SETBP1 SURF1 ZEB2 
ANO5 CBS DPM1 GATM ISPD MID1 NR0B1 POMT1 SHANK2 SYN1 ZFHX4 
ANTXR1 CC2D2A DPYD GCH1 ITGB3 MKKS NR4A2 POMT2 SHANK3 SYNE1 ZFYVE26 
AP1S2 CCBE1 DYM GDI1 ITPR1 MLH1 NRXN1 PORCN SHH SYNGAP1 ZIC2 
AP3B1 CCDC22 DYNC1H1 GFAP KANK1 MLL nrxn1b POU1F1 SHOC2 SYP ZNF41 
APAF1 CCDC39 DYRK1A GJC2 KANSL1 MLL2 NSD1 POU3F4 SHOX TAT ZNF674 
APTX CDH15 EFTUD2 GK KAT6B MLL3 NSDHL PPM1D SHROOM4 TBC1D24   
ARFGEF2 CDK5RAP2 EHMT1 GLDC KCNA1 MLYCD NSUN2 PPOX SIL1 TBR1   
ARHGEF9 CDKL5 EIF2AK3 GLI2 KCNJ10 MMAA NTRK1 PRODH SIX3 TCF4   
ARID1A CDON EIF4G1 GLI3 KCNJ11 MMACHC OBSL1 PRPS1 SKI TFAP2A   
ARID1B CELSR1 ELOVL4 GLRA1 KCNQ2 MMADHC OCA2 PSEN1 SLC12A6 TGFBR1   
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ARL6 CENPJ EP300 GMPPB KCNQ3 MOCS1 OCLN PTCH1 SLC16A2 TGFBR2   
ARSE CEP152 EPHA5 GNAS KCNT1 MOCS2 OCRL PTCHD1 SLC17A5 TGIF1   
ARX CEP290 EPHB2 GNPAT KCTD7 MPDU1 OFD1 PTDSS1 SLC25A15 THRB   
ASL CEP41 ERBB4 GNRHR KDM5C MPDZ OPHN1 PTEN SLC26A9 TIMM8A   
ASPA CHAT ERCC2 GNS KDM6A MSH6 ORC1 PTPN11 SLC2A1 TMEM237 
ASPM CHD2 ERCC3 GP1BB KIAA1279 MTMR2 OTC PVRL1 SLC33A1 TMEM67   
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Supplementary Table 11: List of 628 Candidate ID genes used for prioritization of variants 
Gene 
ABCA2 C16orf62 DDX11 FGD3 KIAA0317 NDUFA1 PPP2R2C SLC25A22 TMLHE ZNF480 
ABCG4 C17orf53 DDX20 FGF22 KIAA1033 NDUFA11 PPP2R5D SLC25A39 TMPRSS12 ZNF526 
ABI3BP C1QTNF6 DDX3X FLVCR1 KIAA1109 NDUFA12 PQBP1 SLC25A5 TNKS2 ZNF565 
ACACB C6orf174 DDX50 FMN2 KIAA1324L NDUFS3 PRDM12 SLC31A1 TNPO2 ZNF592 
ACBD6 C7orf43 DEAF1 FREM3 KIAA1462 NDUFS7 PRDX6 SLC35A2 TNR ZNF673 
ACO2 C9orf86 DENR FRMPD4 KIAA2018 NFASC PRKCA SLC4A10 TOP1 ZNF711 
ACSL4 CA8 DGCR14 FRY KIAA2022 NGEF PRKCB SLC4A8 TRAK1 ZNF81 
ADAT3 CACNA1E DGCR2 GABRB1 KIF14 NISCH PRKRA SLC6A1 TRAPPC11   
ADCY7 CACNA1G DGKH GAD1 KIF1A NLGN2 PRMT10 SLC6A13 TRIM29   
ADK CACNG2 DHDDS GAS2 KIF5C NLRC5 PROX2 SMARCC2 TRIM8   
ADNP CAMK2G DHFR GATAD2B KLF12 NOTUM PRPF39 SMC3 TRIO   
ADRA2B CAP1 DHRS4L1 GCSH KLF8 NPAS4 PRSS12 SMG9 TRIP12   
AGPAT3 CARKD DHTKD1 GIMAP8 KLHL11 NPRL2 PSMA7 SMURF1 TRMT1   
AIFM1 CASP2 DIAPH3 GNAO1 KPNA1 NR2F1 PSMG4 SNIP1 TRMT10A   
AIMP1 CC2D1A DIP2B GOLGA3 KRT80 NRN1 PTGR1 SNX3 TRPC5   
AKR1C4 CCDC137 DIP2C GON4L LAMA1 NTNG1 PTPRK SOBP TRPM3   
ALG2 CCDC18 DLG1 GPD2 LARP7 NUAK1 PTPRM SP7 TRPM5   
ALG9 CCDC78 DLG4 GPR115 LINS NUP54 PTPRR SPAG17 TRPM7   
ALS2CL CCDC8 DLL1 GPR153 LRPPRC NXF5 PTPRT SPATA13 TRRAP   
ALX1 CCDC84 DLX3 GPR84 LTN1 OMG PUS1 SPATA5 TSPAN17   
AMY2B CCNT1 DMPK GPS1 LZTR1 OPLAH PWWP2A SRBD1 TSPYL5   
ANKRD12 CDC42BPB DNAH17 GRB14 MADD OPRL1 RAB2A SRPR TTI2   
ANO10 CDK11A DNAH7 GRIA1 MAGEL2 OR10S1 RAB33B SRPX2 TUBGCP6   
AP2A2 CDK5R1 DNAJB9 GRIA2 MAGT1 OR5M1 RAB39B SSBP3 UBE3B   
AP3B2 CDK6 DNAJC19 GRIK2 MAN1B1 OSBPL5 RAB40AL ST3GAL3 UBE3C   
AP3M1 CDKL3 DNAJC6 GRIN1 MAOA PACS1 RAB5C ST3GAL5 UBN2   
AP4B1 CDS2 DNM1 GRM5 MAPK10 PACS2 RAD21 ST3GAL6 UBQLN1   
AP4E1 CELF2 DNMT3A GRM7 MAPK8IP1 PAFAH1B3 RAD21L1 ST5 UBR3   
AP4S1 CEP135 DOCK9 GSPT2 MBTPS1 PALLD RALGAPB STAG1 UBR5   
APH1A CHAMP1 DPP3 GTF2H5 MCAM PAX1 RALGDS STAP2 UBR7   
ARHGAP30 CHD1 DPP7 GTPBP8 MCM3AP PAX5 RALGPS1 STIL UBTF   
ARHGEF10 CHD3 DRD4 H2AFV MED13 PBRM1 RAPGEF1 STK36 UGGT1   
ARHGEF6 CHD6 DST HARS MED13L PCDH11X RARG STT3A UNC13C   
ARIH1 CHL1 DUS1L HDGFRP2 MED17 PCDH18 RARS STT3B UNC80   
ARL13B CHRNA7 DUSP15 HDLBP MED23 PCDHA13 RASGRP1 STX1B UPF2   
ARMC9 CIC EBAG9 HDX MEGF11 PCDHB13 RASIP1 STXBP3 URB2   
ASAH2 CIT EDA2R HECTD1 MEOX2 PCDHB4 RB1CC1 SUPT16H USP15   
ASB1 CLIC2 EEF1A2 HERC2 METTL14 PCNX RBM10 SV2B USP46   
ASCC3 CLK2 EEF1B2 HIPK3 MGAT4C PCOLCE RBM28 SVIL UTP14C   
ASCL1 CNKSR1 EFHC2 HIST1H1E MIB1 PDCD1 RBMS3 SYNCRIP VCX3A   
ASH1L CNKSR2 EFR3A HIST1H2AE MKLN1 PDIA6 RECK SYNRG VPS37A   
ASNS CNOT1 EIF2C1 HIST1H2AG MLL4 PDIK1L RELN SYT14 WAC   
ATP10D CNOT3 EIF2S3 HIST3H3 MLL5 PDSS1 REPS2 SZT2 WDFY3   
ATP12A CNOT4 ELK1 HIVEP2 MMP27 PDSS2 REST TAAR2 WDR13   
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ATP1B1 CNTN5 ELP2 HTR7 MMP8 PECR RGMA TAF1 WDR45L   
ATP2B4 COG1 EMILIN3 IER3IP1 MOB4 PEX11B RGS14 TAF2 WDR62   
ATP6AP2 COG6 EMX2 IFT81 MPHOSPH8 PGRMC1 RGS7 TAF7L WHSC1L1   
ATP8A2 COG7 ENTPD1 IGBP1 MPP6 PHACTR1 RIMS1 TANC2 XPO1   
B3GNT4 COL25A1 EPB41L1 inpp4a MRPS22 PHF19 RIMS2 TBC1D14 XPO5   
B4GALT1 COL4A3BP EPC2 IQGAP2 MRS2 PHF2 RIOK3 TBC1D7 XPR1   
B4GALT7 COLEC12 ERLIN2 IQSEC1 MTF1 PHIP RMND1 TBCE XYLT1   
BCAP31 COQ5 ESAM ITGA5 MTMR12 PIAS1 RNF38 TBL1XR1 YWHAG   
BCORL1 COX15 EXOC6B JAM3 MTOR PIGL RREB1 TBX18 YY1   
BEST3 CRADD EYA4 JARID2 MYH10 PIGN RRP1B TCF7L1 ZBTB40   
BIRC6 CRBN FAAH2 KANSL2 MYO5A PIGO RTN4RL1 TECPR2 ZBTB41   
BMP1 CRK FAM102A KATNAL2 MYO7B PIGT RUNX1T1 TECR ZC3H12B   
BRAT1 CRTAC1 FAM116B KCNB1 MYOF PIK3R2 RUVBL1 TFDP1 ZC3H14   
BRD4 CSDE1 FAM129B KCNH1 MYT1 PIK3R3 RXFP1 TGM3 ZCCHC12   
BRPF1 CSNK1E FAM13C KCNK12 N6AMT1 PIWIL4 S100G THBS1 ZCCHC8   
BRSK2 CTCF FAM45A KCNK9 NAA10 PLA1A SAP30BP THOC2 ZDHHC15   
BRWD1 CTDP1 FAM63B KDM1A NAA40 PLCL2 SC5DL THOC6 ZFHX3   
BRWD3 CTTNBP2 FAM8A1 KDM1B NACA PLP2 SCAF4 TLK2 ZMYM3   
BTN1A1 CTTNBP2NL FAM91A1 KDM2B NALCN PNPLA7 SCP2 TMC4 ZMYM6   
C10orf11 CUL5 FASN KDM5A NAPRT1 POC1A SDCBP2 TMCO1 ZNF238   
C11orf46 CUX2 FASTKD5 KDM5B NAV2 POGZ SEMA4G TMEM135 ZNF292   
C12orf57 CYP4F3 FAT1 KDM6B NBEA POLR2A SETD5 TMEM165 ZNF385B   
C12orf65 CYTH1 FBXW9 KIAA0100 NCAPD2 POLR2M SFPQ TMEM231 ZNF407   
C15orf38 DBR1 FCRL6 KIAA0182 NCKAP1 POLRMT SLC16A3 TMEM41A ZNF44   
C15orf62 DCAF4 FETUB KIAA0232 NDST1 PPP1R15B SLC1A2 TMEM85 ZNF451   
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Supplementary Table 12: Summary of de novo non-coding SNVs identified in 528 known ID 
genes  
 
Non-coding component Number of mutations 
  Promoter 1 
  5’UTR 2 
  Intron 38 
  Non-canonical splice site 1 
  3’UTR 1 
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Supplementary Table 13: De novo SNVs in non-coding sequence identified in patients with severe ID 
 
Trio Gene Location Genomic annotation cDNA PhyloP 
Predicted 
effect on 
splicing? 
ENCODE 
annotation 
1 LAMA2 Intron Chr6(GRCh37):g.129635764C>T NM_000426.3:c.3412-36C>T -0.59 no   
6 MCOLN1 Intron Chr19(GRCh37):g.7597165G>C NM_020533.2:c.1576-1244G>C -0.44 no   
7 CNTNAP2 Intron Chr7(GRCh37):g.145833308G>T NM_014141.5:c.97+19243G>T 0.21 no   
8 GRM1 Intron Chr6(GRCh37):g.146511626C>T NM_000838.3:c.950+30893C>T -0.36 no   
8 HDAC4 Intron Chr2(GRCh37):g.239978216T>C NM_006037.3:c.2989-1687A>G -0.92 no   
9 LRP2 Splice site Chr2(GRCh37):g.170070389T>C NM_004525.2:c.5827-9A>G -0.02 no   
10 LARGE 5'UTR Chr22(GRCh37):g.34159094C>A NM_004737.4:c.-82-1549G>T -0.42 no   
12 MAP2K1 Intron Chr15(GRCh37):g.66775036A>G NM_002755.3:c.693+819A>G -0.20 no   
13 STXBP1 Intron Chr9(GRCh37):g.130417532G>A NM_003165.3:c.169+1457G>A -0.40 no   
13 AUH Intron Chr9(GRCh37):g.94078475C>T NM_001698.2:c.505+9125G>A 1.57 no   
14 ACVR1 Intron Chr2(GRCh37):g.158654234G>A NM_001105.4:c.67+1705C>T -0.60 no   
16 PNKP Intron Chr19(GRCh37):g.50367525C>T NM_007254.3:c.579-32G>A -0.70 possibly   
17 MCPH1 Intron Chr8(GRCh37):g.6438621C>A NM_024596.3:c.2215-40354C>A -0.44 no   
17 GRM1 Intron Chr6(GRCh37):g.146468131A>G NM_000838.3:c.701-12353A>G 0.04 no   
18 ALG12 Intron Chr22(GRCh37):g.50298304C>T NM_024105.3:c.993-150G>A -2.86 no   
18 GRIN2A Intron Chr16(GRCh37):g.10168818T>C NM_000833.3:c.414+105037A>G 0.04 no   
19 VPS13B Intron Chr8(GRCh37):g.100785479A>G NM_017890.4:c.7323-3524A>G 0.37 no   
20 FOXP1 Intron Chr3(GRCh37):g.71222718G>A NM_001244810.1:c.180+24635C>T 0.12 no   
22 NRXN1 Intron Chr2(GRCh37):g.51178159T>C NM_001135659.1:c.872-25066A>G 0.12 no   
22 NRXN1 Intron Chr2(GRCh37):g.51141214T>C NM_001135659.1:c.931+7793A>G -1.51 no   
22 PVRL1 Intron Chr11(GRCh37):g.119583361G>T NM_002855.4:c.79+15824C>A -1.07 no   
24 SPRED1 Intron Chr15(GRCh37):g.38603586G>A NM_152594.2:c.208-10856G>A -0.44 no   
25 ALDH18A1 5'UTR Chr10(GRCh37):g.97416435_97416438del NM_002860.3:c.-113_-110del - no   
27 MMADHC Promoter Chr2(GRCh37):g.150489713A>G - 0.24 - Weak Promoter; Heterochrom/lo; 
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Repetitive/CNV; 
WeakEnhancer  
28 BBS9 Intron Chr7(GRCh37):g.33191509G>A NM_198428.2:c.113-804G>A -0.44 no   
28 DPYD Intron Chr1(GRCh37):g.97588236C>T NM_000110.3:c.2623-24048G>A 0.93 no   
33 GNPAT Intron Chr1(GRCh37):g.231397861A>G NM_014236.3:c.439-608A>G -1.17 no   
33 SMARCA4 Intron Chr19(GRCh37):g.11086322G>A NM_001128849.1:c.-31-8475G>A -2.30 no   
36 CCBE1 Intron Chr18(GRCh37):g.57124433G>T NM_133459.3:c.554-2250C>A -0.60 no   
36 NF1 Intron Chr17(GRCh37):g.29533557T>C NM_001042492.2:c.1392+168T>C 0.36 no   
38 SETBP1 Intron Chr18(GRCh37):g.42569791G>A NM_015559.2:c.4000+36486G>A -0.04 no   
38 SCN8A Intron Chr12(GRCh37):g.52189411C>T NM_014191.3:c.4795+986C>T -0.76 no   
41 NRXN1 Intron Chr2(GRCh37):g.50558625A>G NM_001135659.1:c.3485-94517T>C -0.28 no   
41 MEF2C Intron Chr5(GRCh37):g.88123620C>T NM_001193347.1:c.-142-3873G>A -1.89 no  
43 BBS9 Intron Chr7(GRCh37):g.33549086C>T NM_198428.2:c.2298+3829C>T 1.66 possibly   
43 PEPD Intron Chr19(GRCh37):g.33980994G>A NM_000285.3:c.442-31C>T -0.36 no   
45 DLG3 Intron ChrX(GRCh37):g.69718156G>A NM_021120.3:c.1820-214G>A -0.12 no   
48 NRXN1 Intron Chr2(GRCh37):g.51078981C>T NM_001135659.1:c.931+70026G>A -1.10 no   
49 CEP290 Intron Chr12(GRCh37):g.88447045C>T NM_025114.3:c.7129+384G>A 0.21 no   
49 ARID1B Intron Chr6(GRCh37):g.157276718A>G NM_020732.3:c.2037+20008A>G 1.50 no   
50 CCBE1 3'UTR Chr18(GRCh37):g.57102290C>T NM_133459.3:c.*850G>A 0.26 miRNA binding?   
50 PLCB1 Intron Chr20(GRCh37):g.8327174C>T NM_015192.2:c.178-24855C>T 0.22 no   
50 SHROOM4 Intron ChrX(GRCh37):g.50462314T>C NM_020717.3:c.118-23377A>G 0.53 no   
 
Confirmed non-coding de novo mutations. Effect on splicing was determined using Alamut software that integrates a number of prediction methods for splice signal 
detection as well as exonic splicing enhancer (ESE) binding site detection. Encode annotation was based on Chromatin state segments of nine human cell types (Broad 
ChromHMM) and transcription factor binding sites (Txn Factor ChIP).41  
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Supplementary Table 14: Phenotypic comparison of patients with mutations in known and candidate ID genes 
 
Trio Phenotype Mutation 
type 
Gene Disease association References 
5 Severe ID, signs of autism, aggressive behavior, 2 café 
au lait spots, increased pain threshold.  
CNV SHANK3                           
[OMIM 606232] 
Phelan-McDermid syndrome is characterized by neonatal hypotonia, 
global developmental delay, absent to severely delayed speech, and 
normal to accelerated growth. Behavior characteristics include 
mouthing or chewing non-food items, decreased perception of pain, 
and autistic-like affect. Phelan-McDermid syndrome can be caused by 
a heterozygous contiguous gene deletion at chromosome 22q13 or by 
mutation in the SHANK3 gene.  
80,81 
          
7 Developmental delay. No major dysmorphisms. SNV TBR1                                   
[OMIM 604616] 
TBR1, a transcription factor involved in early cortical development, is a 
strong candidate for the intellectual disability phenotype seen in 
patients with 2q24.3 deletions. De novo mutations in TBR1 have also 
been reported in individuals with autism. 
49,82 
          
9 ID from infancy. Regression at adult age. She showed 
parkinsonism and dystonia. 
SNV WDR45                       
[OMIM 300526] 
Neurodegeneration with brain iron accumulation (NBIA) is a group of 
genetic disorders characterized by abnormal iron deposition in the 
basal ganglia. De novo mutations in WDR45, encoding a beta-propeller 
scaffold protein with a putative role in autophagy, cause a distinctive 
NBIA phenotype. The clinical features include early-onset global 
developmental delay and further neurological deterioration 
(parkinsonism, dystonia, and dementia developing by early 
adulthood). 
83,84 
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12 ID  without speech, autism. Hypotonia. Recurrent 
infection. Sleep disturbances, delayed puberty and 
obesitas. Short stature and microcephaly. Deep set 
eyes, hypertelorism,  large ears, large nose, short 
philtrum, full lips. Kyphosis, narrow hands with 
tapering fingers, partial cutaneous syndactyly of 2nd 
and 3rd toes and sandal gaps. No ophthalmologic 
anomalies.  
 
Of note, Cohen syndrome was part of the differential 
diagnosis. VPS13B was sequenced but with normal 
results. 
CNV VPS13B 
[OMIM 216550] 
Cohen syndrome is an autosomal recessive disorder characterized by 
a characteristic facial appearance, failure to thrive, microcephaly, 
progressive retinochoroidal dystrophy and high myopia, neutropenia 
with recurrent infections, a cheerful disposition, joint hypermobility, 
truncal obesity in puberty, early-onset hypotonia and moderate-
profound ID. 
85
 
      
13 Severe ID with epilepsy. No speech. Short stature, 
microcephaly and enlarged ventricles and hypertrophy 
of the cerebellar vermis. Hypotonia, cleft palate, 
cataract, scoliosis and stereotypic movements. 
Dysmorphic features included a low frontal-temporal 
hairline, deep-set eyes, a flat midface, long narrow 
ears, a long nose with a high bridge, a short philtrum, 
an everted lower lip and a prominent jaw. In addition, 
she had scoliosis, short narrow hands, tapered fingers 
and several contractures. 
SNV SMC1A                              
[OMIM 610759]  
Cornelia de Lange syndrome CdLS is a clinically and genetically 
heterogeneous developmental disorder. Clinical features include 
growth retardation, intellectual disability, limb defects, arched 
eyebrows, synophrys thin lips and other systemic involvement. 
Mutations in SMC1A are associated with a milder phenotype with 
moderate neurocognitive impairment and a paucity of major 
structural defects. Recently, one loss-of-function mutation was 
described in a female patient with developmental delay, 
microcephaly, congenital diaphragmatic hernia, and generalized 
epilepsy. Dysmorphic features included round face with arched 
eyebrows, short nose, smoothed philtrum, prominent jaw, 
clinodactyly of the 5th fingers and camptodactyly of the 5th finger on 
the right.  
78,86-88 
      
15 Neonatal feeding problems, hip dysplasia. ID (IQ 50) 
and autism.  Epicanthic folds, straight eyebrows, 
posteriorly rotated ears and downturned corners of 
the mouth. MRI of brain is not available. No epilepsy. 
SNV SPTAN1                               
[OMIM 613417] 
Epileptic encephalopathy, early infantile, 5 (EIEE5). SPTAN1 mutations 
have been reported in patients with severe ID, infantile spasms with 
hypsarrhythmia, hypomyelnation and atrophy of various regions of 
the brain, including the cerebellum and brainstem. Mutations have 
also been reported in a patients with non-syndromic ID.  
89
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26 ID (dyshormonic profile; performal IQ 50, verbal 90), 
hypotonia, no facial dysmorphisms, progressive 
scoliosis, hip dysplasia, fatigue problems.  
SNV PPP2R5D                      
[OMIM 601646] 
Recently, we published a patient with a de novo mutation in PPP2R5D 
was identified. The patient presented with ID, absence of speech, no 
facial dysmorphisms, short stature, microcephaly, cataract, anxiety, 
autistic features and mood swings. The product of this gene belongs 
to the phosphatase 2A regulatory subunit B family. Protein 
phosphatase 2A is one of the four major Ser/Thr phosphatases, and it 
is implicated in the negative control of cell growth and division.   
32
 
      
27 Severe ID. Epilepsy (tonic-clonic seizures), myokymia. 
Normal height, head circumference  -2 SD. Broad 
based walking pattern. Narrow long face, prominent 
supraorbital ridges, long nose and philtrum,  thin 
upper lip, hypodontia, long fingers and toes and 
narrow thorax. 
SNV KCNA1 
[OMIM 160120]  
Mutations in KCNA1 have been reported in patients with episodic 
ataxia and myokymia, without ID. In one report a family with 
persistent cerebellar dysfunction, cerebellar atrophy, and cognitive 
delay has been described. All affected family members had myokymia 
and epilepsy. Additional features included postural abnormalities, 
episodic stiffness and weakness.   
 
 
94
 
          
28 ID. No  major dysmorphisms. No epilepsy. Sleep 
disturbances and obsessive behaviour. 
SNV SCN2A                         
[OMIM 182390] 
SCN2A mutations have been reported in patients with early-onset 
infantile epileptic encephalopathy and also in patients with severe ID 
and auto-aggressive behavior but without epilepsy.  
32,45 
          
31 Severe ID, microcephaly, epilepsy, progressive 
spasticity, small hands and feet, poor vision.  
CNV TENM3                                  
[OMIM 610083]                   
IQSEC2                         
[OMIM 309530] 
IQSEC2 is a non-syndromic X-linked ID gene in which  carrier females 
show normal or mild learning difficulties. Male patients, show  
phenotypic overlap with pathogenic mutations in MECP2, FOXG1, 
CDKL5 and MEF2C, but may also manifest seizures, autistic-like 
behavior, psychiatric problems and delayed language skills. In most 
male patients the mutation occurred de novo (rather than maternally 
inherited). One other female patient with severe infantile spasms, 
profound global developmental arrest, hypsarrhythmia and severe ID, 
is reported to have a balanced translocation that disrupts IQSEC2. 
45,95-97 
          
40 Moderate ID, features of autism, anxiety, mood 
instability and aggressive outbursts. No evident 
dysmorphic features. 
CNV STAG1  
[OMIM 604358] 
 
A de novo loss of function mutation was previously reported as a 
possible cause for ID in a patient with normal growth and head 
circumference.  
45
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43 Moderate ID,left hydronephrosis , right dysplastic 
kidney, severe hypermetropia, Horner syndrome, 
microcephaly . 
SNV POGZ                            
[OMIM 614787] 
Mutations in POGZ have been identified in patients with autism.  47,48 
          
46 Severe hypotonia, severe motor delay and speech 
delay. Deficient gyration frontal region, mild 
periventricular white matter abnormalities 
SNV TBR1                                   
[OMIM 604616] 
TBR1, a transcription factor involved in early cortical development, is a 
strong candidate for the intellectual disability phenotype seen in 
patients with 2q24.3 deletions. De novo mutations in TBR1 have also 
been reported in individuals with autism.  
49,82 
    
 
 
48 Severe ID, severe epilepsy, Rett-like phenotype, motor 
handicap, severe feeding difficulties, progressive 
scoliosis 
CNV SMC1A                              
[OMIM 610759]  
Cornelia de Lange syndrome CdLS is a clinically and genetically 
heterogeneous developmental disorder. Clinical features include 
growth retardation, intellectual disability, limb defects, arched 
eyebrows, synophrys thin lips and other systemic involvement. 
Mutations in SMC1A are associated with a milder phenotype with 
moderate neurocognitive impairment and a paucity of major 
structural defects. Recently, one loss-of-function mutation was 
described in a female patient with developmental delay, 
microcephaly, congenital diaphragmatic hernia, and generalized 
epilepsy. Dysmorphic features included round face with arched 
eyebrows, short nose, smoothed philtrum, prominent jaw, 
clinodactyly of the 5th fingers and camptodactyly of the 5th finger on 
the right. 
 
78,86-88 
          
50 Profound ID, microcephaly, short stature, vaginal 
atresia, unilateral renal agenesis, cortical blindness, 
evident dysmorphic features, small hands and feet 
CNV Proximal 16p11.2 
deletion                       
[OMIM 611913] 
Patients with the typical 600 kb 16p11 deletion can have borderline-
mild ID, psychiatric disorders (80%), obesity (50%) and seizures (25%). 
This locus is known for its reduced penetrance (estimated at to be 
47%), with the majority of CNVs occurring de novo (70% of cases). 
Eight percent of patients show additional variants expected to 
contribute to the phenotype. Such variant may also be expected in 
this patient. 
98-100
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Supplementary Table 15: Molecular diagnosis per patient after WGS 
 
Trio Molecular diagnosis?* Based on [gene] (inheritance) Mutation type 
1 Possible NGFR (de novo) Autosomal SNV 
2 Possible GFPT2 (de novo) Autosomal SNV 
3 NO   
4 NO   
5 Highly likely SHANK3 (de novo) Autosomal CNV 
6 Possible WWP2 (de novo) Autosomal SNV 
7 Highly Likely TBR1 (de novo) Autosomal SNV 
8 NO   
9 Highly likely WDR45 (de novo) X-linked SNV 
10 NO   
11 NO   
12 Highly likely VPS13B (inherited) Autsomal CNV 
13 Highly likely SMC1A (de novo) X-linked SNV 
14 NO   
15 Highly likely SPTAN (de novo) Autosomal SNV 
16 NO   
17 Possible ASUN (de novo) Autosomal SNV 
18 Highly likely MECP2 (de novo) X-linked CNV 
19 NO   
20 NO   
21 Highly likely RAI1 (de novo) Autosomal SNV 
22 Highly likely MED13L (de novo) Autosomal SNV 
23 NO   
24 Possible BRD3 (de novo) Autosomal SNV 
25 Highly likely SATB2 (de novo) Autosomal SNV 
26 Highly likely PPP2R5D (de novo) Autosomal SNV 
27 Highly likely KCNA1 (de novo) Autosomal SNV 
28 Highly likely SCN2A (de novo) Autosomal SNV 
29 NO   
30 Possible MAST1 (de novo) Autosomal SNV 
31 Highly likely IQSEC2 (de novo) Autosomal CNV/ X-linked   
32 NO   
33 NO   
34 Possible APPL2 (de novo) Autosomal SNV 
35 NO   
36 NO   
37 Highly likely multiple (de  novo)* Autosomal CNV 
38 NO   
39 NO   
40 Highly likely STAG1 (de novo) Autosomal CNV 
41 Possible NACC1 (de novo) Autosomal SNV 
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42 NO   
43 Highly likely POGZ (de novo) Autosomal SNV 
44 NO   
45 NO   
46 Highly likely TBR1 (de novo) Autosomal SNV 
47 NO   
48 Highly likely SMC1A (de novo) X-linked CNV 
49 Highly likely KANSL2 (de novo) Autosomal SNV 
50 Highly likely 16p11.2 microdeletion syndrome (de novo) Autosomal CNV 
 
*Of note, a possible diagnosis was made in 8 patients who showed severe de novo SNVs in genes with 
functional support for ID-related disorders (Extended Data Table 2). Interestingly these 8 genes showed a 
significantly lower tolerance for normal variation similar to our set of known and candidate ID genes (P=0.003, 
Extended Data Figure 1). Nonetheless, conclusive diagnoses for these 8 patients cannot be made based on 
single observations and are thus not included in the calculated diagnostic yields. **48 genes are affected by the 
rearrangement – phenotype may be the effect of a single dosis sensitive gene in this CNV or it may reflect a 
contiguous gene syndrome, with multiple genes contributing.  
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